{ "instance": { "zk2329404.htm": { "axisCustom": 1, "axisStandard": 21, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 40, "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 820 }, "contextCount": 294, "dts": { "calculationLink": { "local": [ "blrx-20221231_cal.xml" ] }, "definitionLink": { "local": [ "blrx-20221231_def.xml" ] }, "inline": { "local": [ "zk2329404.htm" ] }, "labelLink": { "local": [ "blrx-20221231_lab.xml" ] }, "presentationLink": { "local": [ "blrx-20221231_pre.xml" ] }, "schema": { "local": [ "blrx-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 575, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 111, "keyStandard": 218, "memberCustom": 41, "memberStandard": 27, "nsprefix": "blrx", "nsuri": "http://biolinerx.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://biolinerx.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0010 - Disclosure - CASH AND CASH EQUIVALENTS", "menuCat": "Notes", "order": "10", "role": "http://biolinerx.com/role/CashAndCashEquivalents", "shortName": "CASH AND CASH EQUIVALENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDepositsFromBanksExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0011 - Disclosure - SHORT-TERM BANK DEPOSITS", "menuCat": "Notes", "order": "11", "role": "http://biolinerx.com/role/Short-termBankDeposits", "shortName": "SHORT-TERM BANK DEPOSITS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDepositsFromBanksExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0012 - Disclosure - PROPERTY AND EQUIPMENT", "menuCat": "Notes", "order": "12", "role": "http://biolinerx.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0013 - Disclosure - INTANGIBLE ASSETS", "menuCat": "Notes", "order": "13", "role": "http://biolinerx.com/role/IntangibleAssets", "shortName": "INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0014 - Disclosure - LEASES", "menuCat": "Notes", "order": "14", "role": "http://biolinerx.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0015 - Disclosure - LONG-TERM LOANS", "menuCat": "Notes", "order": "15", "role": "http://biolinerx.com/role/Long-termLoans", "shortName": "LONG-TERM LOANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0016 - Disclosure - EQUITY", "menuCat": "Notes", "order": "16", "role": "http://biolinerx.com/role/Equity", "shortName": "EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0017 - Disclosure - TAXES ON INCOME", "menuCat": "Notes", "order": "17", "role": "http://biolinerx.com/role/TaxesOnIncome", "shortName": "TAXES ON INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0018 - Disclosure - LOSS PER SHARE", "menuCat": "Notes", "order": "18", "role": "http://biolinerx.com/role/LossPerShare", "shortName": "LOSS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0019 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES", "menuCat": "Notes", "order": "19", "role": "http://biolinerx.com/role/CommitmentsAndContingentLiabilities", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0002 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "menuCat": "Statements", "order": "2", "role": "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "lang": null, "name": "ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0020 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES", "menuCat": "Notes", "order": "20", "role": "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedParties", "shortName": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0021 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION", "menuCat": "Notes", "order": "21", "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformation", "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "22", "role": "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "23", "role": "http://biolinerx.com/role/SignificantAccountingPoliciesTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0024 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables)", "menuCat": "Tables", "order": "24", "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables", "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0025 - Disclosure - CASH AND CASH EQUIVALENTS (Tables)", "menuCat": "Tables", "order": "25", "role": "http://biolinerx.com/role/CashAndCashEquivalentsTables", "shortName": "CASH AND CASH EQUIVALENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "menuCat": "Tables", "order": "26", "role": "http://biolinerx.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0027 - Disclosure - INTANGIBLE ASSETS (Tables)", "menuCat": "Tables", "order": "27", "role": "http://biolinerx.com/role/IntangibleAssetsTables", "shortName": "INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0028 - Disclosure - LEASES (Tables)", "menuCat": "Tables", "order": "28", "role": "http://biolinerx.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0030 - Disclosure - EQUITY (Tables)", "menuCat": "Tables", "order": "29", "role": "http://biolinerx.com/role/EquityTables", "shortName": "EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "menuCat": "Statements", "order": "3", "role": "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "lang": null, "name": "ifrs-full:ProfitLossFromOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0031 - Disclosure - TAXES ON INCOME (Tables)", "menuCat": "Tables", "order": "30", "role": "http://biolinerx.com/role/TaxesOnIncomeTables", "shortName": "TAXES ON INCOME (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0032 - Disclosure - LOSS PER SHARE (Tables)", "menuCat": "Tables", "order": "31", "role": "http://biolinerx.com/role/LossPerShareTables", "shortName": "LOSS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0033 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Tables)", "menuCat": "Tables", "order": "32", "role": "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesTables", "shortName": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0034 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)", "menuCat": "Tables", "order": "33", "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables", "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RetainedEarnings", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0035 - Disclosure - GENERAL INFORMATION (Narrative) (Details)", "menuCat": "Details", "order": "34", "role": "http://biolinerx.com/role/GeneralInformationDetails", "shortName": "GENERAL INFORMATION (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:EmployeeBenefitsExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "menuCat": "Details", "order": "35", "role": "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:EmployeeBenefitsExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "blrx:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0037 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates) (Details)", "menuCat": "Details", "order": "36", "role": "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "blrx:DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory", "div", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "div", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0038 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life of Right of Use Assets) (Details)", "menuCat": "Details", "order": "37", "role": "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life of Right of Use Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory", "div", "div", "div", "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "div", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231_ifrsfullClassesOfAssetsAxis_ifrsfullLandAndBuildingsMember", "decimals": null, "first": true, "lang": "en-US", "name": "blrx:DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:FinancialLiabilitiesAtFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0039 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Narrative) (Details)", "menuCat": "Details", "order": "38", "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails", "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxWarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:FinancialLiabilitiesAtFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember", "decimals": "-3", "first": true, "lang": null, "name": "blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0040 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details)", "menuCat": "Details", "order": "39", "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails", "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231_ifrsfullClassesOfFinancialInstrumentsAxis_blrxCashAndCashEquivalentMember", "decimals": "-3", "first": true, "lang": null, "name": "blrx:TenPercentIncreaseEffectOnNetIncomeLossAndEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20191231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "menuCat": "Statements", "order": "4", "role": "http://biolinerx.com/role/StatementsOfChangesInEquity", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20191231_ifrsfullComponentsOfEquityAxis_ifrsfullIssuedCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231_ifrsfullTypesOfRisksAxis_blrxNisPerDollarMember", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:ClosingForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "Rate_per_Dollar", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0041 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Concentration of Currency Risk) (Details)", "menuCat": "Details", "order": "40", "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails", "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Concentration of Currency Risk) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231_ifrsfullTypesOfRisksAxis_blrxNisPerDollarMember", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:ClosingForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "Rate_per_Dollar", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0042 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Linkage of Monetary Items) (Details)", "menuCat": "Details", "order": "41", "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails", "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Linkage of Monetary Items) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "blrx:DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231_ifrsfullTypesOfRisksAxis_blrxDollarMember", "decimals": "-3", "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0043 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Credit Risk) (Details)", "menuCat": "Details", "order": "42", "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails", "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Credit Risk) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231_ifrsfullTypesOfRisksAxis_ifrsfullCreditRiskMember", "decimals": "-3", "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "span", "span", "div", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0044 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Changes in Financial Liabilities With Cash Flows) (Details)", "menuCat": "Details", "order": "43", "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails", "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Changes in Financial Liabilities With Cash Flows) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "lang": null, "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20211231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember", "decimals": "-3", "first": true, "lang": null, "name": "blrx:FairValueOfWarrants", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0045 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Value Measurement of Warrants) (Details)", "menuCat": "Details", "order": "44", "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails", "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Value Measurement of Warrants) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "div", "div", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20191231_ifrsfullLevelsOfFairValueHierarchyAxis_ifrsfullLevel3OfFairValueHierarchyMember", "decimals": "-3", "lang": null, "name": "blrx:FairValueOfWarrants", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember", "decimals": "4", "first": true, "lang": null, "name": "blrx:InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0046 - Disclosure - CASH AND CASH EQUIVALENTS (Narrative) (Details)", "menuCat": "Details", "order": "45", "role": "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails", "shortName": "CASH AND CASH EQUIVALENTS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember", "decimals": "4", "first": true, "lang": null, "name": "blrx:InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0047 - Disclosure - CASH AND CASH EQUIVALENTS (Schedule of Cash And Cash Equivalents) (Details)", "menuCat": "Details", "order": "46", "role": "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "shortName": "CASH AND CASH EQUIVALENTS (Schedule of Cash And Cash Equivalents) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "div", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "ifrs-full:DisclosureOfDepositsFromBanksExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember", "decimals": "4", "first": true, "lang": null, "name": "blrx:InterestRateOnShortTermDeposits", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0048 - Disclosure - SHORT-TERM BANK DEPOSITS (Narrative) (Details)", "menuCat": "Details", "order": "47", "role": "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails", "shortName": "SHORT-TERM BANK DEPOSITS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "ifrs-full:DisclosureOfDepositsFromBanksExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231_ifrsfullRangeAxis_ifrsfullBottomOfRangeMember", "decimals": "4", "first": true, "lang": null, "name": "blrx:InterestRateOnShortTermDeposits", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0049 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Composition of Property and Equipment and Related Accumulated Depreciation) (Details)", "menuCat": "Details", "order": "48", "role": "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails", "shortName": "PROPERTY AND EQUIPMENT (Schedule of Composition of Property and Equipment and Related Accumulated Depreciation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "div", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20211231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember", "decimals": "-3", "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231_ifrsfullBusinessCombinationsAxis_blrxAgalimmuneLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0050 - Disclosure - INTANGIBLE ASSETS (Narrative) (Details)", "menuCat": "Details", "order": "49", "role": "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails", "shortName": "INTANGIBLE ASSETS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231_ifrsfullBusinessCombinationsAxis_blrxAgalimmuneLtdMember_ifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrsfullOtherIntangibleAssetsMember", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "5", "role": "http://biolinerx.com/role/ConsolidatedCashFlowStatements", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "lang": null, "name": "ifrs-full:CashFlowsFromUsedInOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0051 - Disclosure - INTANGIBLE ASSETS (Schedule of Intangible Assets) (Details)", "menuCat": "Details", "order": "50", "role": "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails", "shortName": "INTANGIBLE ASSETS (Schedule of Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "div", "div", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20211231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember", "decimals": "-3", "lang": null, "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "0", "first": true, "lang": null, "name": "blrx:NumberOfPremises", "reportCount": 1, "unique": true, "unitRef": "Premises", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0052 - Disclosure - LEASES (Narrative) (Details)", "menuCat": "Details", "order": "51", "role": "http://biolinerx.com/role/LeasesNarrativeDetails", "shortName": "LEASES (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "0", "first": true, "lang": null, "name": "blrx:NumberOfPremises", "reportCount": 1, "unique": true, "unitRef": "Premises", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0053 - Disclosure - LEASES (Schedule of Right-of-use assets) (Details)", "menuCat": "Details", "order": "52", "role": "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "shortName": "LEASES (Schedule of Right-of-use assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20211231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_blrxNetBookValueMember", "decimals": "-3", "lang": null, "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0054 - Disclosure - LEASES (Schedule of Lease Liabilities) (Details)", "menuCat": "Details", "order": "53", "role": "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails", "shortName": "LEASES (Schedule of Lease Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20211231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0055 - Disclosure - LEASES (Schedule of Minimum Future Rental Payments) (Details)", "menuCat": "Details", "order": "54", "role": "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails", "shortName": "LEASES (Schedule of Minimum Future Rental Payments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "div", "div", "ifrs-full:DisclosureOfLeasesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "span", "span", "span", "p", "div", "div", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20181001to20181031", "decimals": "-6", "first": true, "lang": null, "name": "blrx:LoanTakenForPaymentOfAgreementValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0056 - Disclosure - LONG-TERM LOANS (Narrative) (Details)", "menuCat": "Details", "order": "55", "role": "http://biolinerx.com/role/Long-termLoansNarrativeDetails", "shortName": "LONG-TERM LOANS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "span", "p", "div", "div", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20181001to20181031", "decimals": "-6", "first": true, "lang": null, "name": "blrx:LoanTakenForPaymentOfAgreementValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0058 - Disclosure - EQUITY (Narrative) (Details)", "menuCat": "Details", "order": "56", "role": "http://biolinerx.com/role/EquityNarrativeDetails", "shortName": "EQUITY (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesAuthorised", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0059 - Disclosure - EQUITY (Schedule of Share Capital) (Details)", "menuCat": "Details", "order": "57", "role": "http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails", "shortName": "EQUITY (Schedule of Share Capital) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "0", "lang": null, "name": "blrx:AuthorizedShareCapitalValue", "reportCount": 1, "unique": true, "unitRef": "ILS", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20211231", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0060 - Disclosure - EQUITY (Schedule of Amounts Outstanding Under Employee Share Incentive Plan) (Details)", "menuCat": "Details", "order": "58", "role": "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails", "shortName": "EQUITY (Schedule of Amounts Outstanding Under Employee Share Incentive Plan) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20191231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_blrxEmployeesAndDirectorsMember", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0061 - Disclosure - EQUITY (Schedule of Options Outstanding by Exercise Price Range) (Details)", "menuCat": "Details", "order": "59", "role": "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails", "shortName": "EQUITY (Schedule of Options Outstanding by Exercise Price Range) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231_ifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis_blrxExercisePriceRangeMember", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0006 - Disclosure - GENERAL INFORMATION", "menuCat": "Notes", "order": "6", "role": "http://biolinerx.com/role/GeneralInformation", "shortName": "GENERAL INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0062 - Disclosure - EQUITY (Schedule of Assumptions Used to Value Options) (Details)", "menuCat": "Details", "order": "60", "role": "http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails", "shortName": "EQUITY (Schedule of Assumptions Used to Value Options) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "div", "div", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:ApplicableTaxRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0063 - Disclosure - TAXES ON INCOME (Narrative) (Details)", "menuCat": "Details", "order": "61", "role": "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails", "shortName": "TAXES ON INCOME (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "div", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "2", "lang": null, "name": "blrx:WithholdingApplicableTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:ApplicableTaxRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0064 - Disclosure - TAXES ON INCOME (Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income) (Details)", "menuCat": "Details", "order": "62", "role": "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails", "shortName": "TAXES ON INCOME (Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory", "div", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "lang": null, "name": "ifrs-full:AccountingProfit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0065 - Disclosure - LOSS PER SHARE (Schedule of Basic Loss Per Share) (Details)", "menuCat": "Details", "order": "63", "role": "http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails", "shortName": "LOSS PER SHARE (Schedule of Basic Loss Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "span", "span", "div", "div", "div", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "2", "first": true, "lang": null, "name": "blrx:RoyaltiesReceivedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0066 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)", "menuCat": "Details", "order": "64", "role": "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "div", "div", "div", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "2", "first": true, "lang": null, "name": "blrx:RoyaltiesReceivedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0067 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Transactions With Related Parties) (Details)", "menuCat": "Details", "order": "65", "role": "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails", "shortName": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Transactions With Related Parties) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "table", "div", "div", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231_ifrsfullSeparateManagementEntitiesAxis_blrxSeniorManagementMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "div", "div", "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0068 - Disclosure - TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Key Management Compensation) (Details)", "menuCat": "Details", "order": "66", "role": "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails", "shortName": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Key Management Compensation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "div", "div", "ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory", "div", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "first": true, "lang": null, "name": "blrx:InstitutionsCurrentReceivables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0069 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Receivables) (Details)", "menuCat": "Details", "order": "67", "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails", "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Receivables) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "blrx:DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory", "div", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "first": true, "lang": null, "name": "blrx:InstitutionsCurrentReceivables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "blrx:DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory", "div", "div", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "first": true, "lang": null, "name": "blrx:TradeAndOtherPayablesToForeignTradeSuppliers", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0070 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Accounts Payable and Accruals) (Details)", "menuCat": "Details", "order": "68", "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails", "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Accounts Payable and Accruals) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "blrx:DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory", "div", "div", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20221231", "decimals": "-3", "first": true, "lang": null, "name": "blrx:TradeAndOtherPayablesToForeignTradeSuppliers", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "blrx:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ServicesExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0071 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Research and Development Expenses) (Details)", "menuCat": "Details", "order": "69", "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails", "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Research and Development Expenses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "blrx:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ServicesExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "7", "role": "http://biolinerx.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "blrx:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "blrx:MarketingExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0072 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Sales and Marketing Expenses) (Details)", "menuCat": "Details", "order": "70", "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails", "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Sales and Marketing Expenses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "blrx:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "blrx:MarketingExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "blrx:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0073 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of General and Administrative Expense) (Details)", "menuCat": "Details", "order": "71", "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails", "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of General and Administrative Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "blrx:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "blrx:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ShareIssueRelatedCost", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0074 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Non-Operating Income (Expenses), Net) (Details)", "menuCat": "Details", "order": "72", "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails", "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Non-Operating Income (Expenses), Net) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "blrx:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "lang": null, "name": "ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "blrx:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0075 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Income) (Details)", "menuCat": "Details", "order": "73", "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails", "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Income) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "blrx:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "blrx:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0076 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Expenses) (Details)", "menuCat": "Details", "order": "74", "role": "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails", "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Expenses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "blrx:DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "div", "blrx:DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0008 - Disclosure - FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT", "menuCat": "Notes", "order": "8", "role": "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagement", "shortName": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0009 - Disclosure - CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS", "menuCat": "Notes", "order": "9", "role": "http://biolinerx.com/role/CriticalAccountingEstimatesAndJudgments", "shortName": "CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "zk2329404.htm", "contextRef": "C_20220101to20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 71, "tag": { "blrx_AccountsPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts payable.", "label": "Accounts Payable Abstract", "terseLabel": "Accounts payable:" } } }, "localname": "AccountsPayableAbstract", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" ], "xbrltype": "stringItemType" }, "blrx_AdditionalCommitmentFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional commitment fee.", "label": "Additional commitment fee" } } }, "localname": "AdditionalCommitmentFee", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_AdditionalExtendLeasePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional extend the lease period.", "label": "Additional Extend Lease Period", "terseLabel": "Additional extension period" } } }, "localname": "AdditionalExtendLeasePeriod", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "blrx_AdditionsLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Addition in lease liabilities.", "label": "Additions Lease Liabilities", "verboseLabel": "Additions during year" } } }, "localname": "AdditionsLeaseLiabilities", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 10.0, "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease (increase) in prepaid expense other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Decrease Increase In Prepaid Expenses And Other Operating Receivables", "negatedLabel": "Decrease (increase) in prepaid expenses and other receivables" } } }, "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments Required To Reflect Net Cash Used In Operating Activities Abstract", "terseLabel": "Adjustments required to reflect net cash used in operating activities:" } } }, "localname": "AdjustmentsRequiredToReflectNetCashUsedInOperatingActivitiesAbstract", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "stringItemType" }, "blrx_AgalimmuneLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agalimmune Ltd. [Member]", "label": "Agalimmune Ltd. [Member]" } } }, "localname": "AgalimmuneLtdMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_AggregateOfferingPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate offering price.", "label": "Aggregate offering price" } } }, "localname": "AggregateOfferingPrice", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ADSs [Member]", "label": "American Depositary Shares Member", "terseLabel": "ADSs [Member]" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_AmountAllocatedToWarrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to warrant.", "label": "Amount allocated to warrant" } } }, "localname": "AmountAllocatedToWarrant", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_AmountGrantOfEquityInstruments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount granted for equity instruments.", "label": "Amount Grant Of Equity Instruments", "terseLabel": "Amount granted for equity instruments" } } }, "localname": "AmountGrantOfEquityInstruments", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_AmountOfIntellectualPropertyAndCashBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents amount of intellectual property and cash balance.", "label": "Amount Of Intellectual Property And Cash Balance", "verboseLabel": "Amount of intellectual property and cash balance" } } }, "localname": "AmountOfIntellectualPropertyAndCashBalance", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_AmountOfLoanAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents amount of loan agreement.", "label": "Amount Of Loan Agreement", "verboseLabel": "Amount of loan agreement" } } }, "localname": "AmountOfLoanAgreement", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_AnnualLeaseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Annual Lease fee.", "label": "Annual Lease fee" } } }, "localname": "AnnualLeaseFee", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_AuthorizedShareCapitalValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of authorized share capital.", "label": "Authorized Share Capital Value", "verboseLabel": "Authorized share capital" } } }, "localname": "AuthorizedShareCapitalValue", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "blrx_AvailableBalanceUnderFacility": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Available balance under the facility", "label": "Available balance under the facility" } } }, "localname": "AvailableBalanceUnderFacility", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_BankGuaranteeAmountForBenefitOfLessor": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Bank guarantee amount for benefit of Lessor.", "label": "Bank guarantee amount for benefit of lessor" } } }, "localname": "BankGuaranteeAmountForBenefitOfLessor", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_BenefitsToRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Benefits to related parties.", "label": "Benefits To Related Parties Abstract", "terseLabel": "Benefits to related parties:" } } }, "localname": "BenefitsToRelatedPartiesAbstract", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "blrx_BiokineTherapeuticsLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biokine Therapeutics Ltd [Member]", "label": "Biokine Therapeutics Ltd [Member]", "terseLabel": "Biokine [Member]" } } }, "localname": "BiokineTherapeuticsLtdMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails", "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_BostonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Boston", "label": "Boston [Member]", "verboseLabel": "Boston [Member]" } } }, "localname": "BostonMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_BtigLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BTIG, LLC [Member]", "label": "BTIG, LLC [Member]" } } }, "localname": "BtigLlcMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_BvfPartnersLpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BVF Partners L.P. [Member]", "label": "Bvf Partners Lp Member", "terseLabel": "BVF Partners L.P. [Member]" } } }, "localname": "BvfPartnersLpMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_CashAndCashEquivalentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents [Member]", "label": "Cash And Cash Equivalent [Member]", "terseLabel": "Cash and cash equivalents [Member]" } } }, "localname": "CashAndCashEquivalentMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "blrx_ChangesInFairValueThroughProfitAndLossOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Changes in fair value through profit and loss.", "label": "Changes In Fair Value Through Profit And Loss Of Warrants", "terseLabel": "Changes in fair value through profit and loss" } } }, "localname": "ChangesInFairValueThroughProfitAndLossOfWarrants", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_ChangesInOperatingAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes In Operating Assets And Liabilities Abstract", "terseLabel": "Changes in operating asset and liability items:" } } }, "localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "stringItemType" }, "blrx_CommitmentsAndContingentLiabilities": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 20.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Commitment and contingent liabilities.", "label": "COMMITMENTS AND CONTINGENT LIABILITIES" } } }, "localname": "CommitmentsAndContingentLiabilities", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "blrx_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultants [Member]", "label": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_ContingentLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the value of contingent liability.", "label": "Contingent Liability", "verboseLabel": "Value of contingent liability" } } }, "localname": "ContingentLiability", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_DeletionsLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deletions in lease liabilities.", "label": "Deletions Lease Liabilities", "negatedLabel": "Deletions during year", "terseLabel": "Deletions during year" } } }, "localname": "DeletionsLeaseLiabilities", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_DeletionsToRightOfUseAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of deletions to right-of-use assets.", "label": "Deletions To Right Of Use Assets", "terseLabel": "Deletions during year" } } }, "localname": "DeletionsToRightOfUseAssets", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for changes in accounting policies and disclosures.", "label": "Description Of Accounting Policy For Change In Accounting Policy And Disclosures Explanatory", "terseLabel": "New standards and interpretations not yet adopted" } } }, "localname": "DescriptionOfAccountingPolicyForChangeInAccountingPolicyAndDisclosuresExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "blrx_DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for Changes in accounting policies.", "label": "Description Of Accounting Policy For Change In Accounting Policy Explanatory", "terseLabel": "Changes in accounting policies" } } }, "localname": "DescriptionOfAccountingPolicyForChangeInAccountingPolicyExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "blrx_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for principles of consolidation.", "label": "Description Of Accounting Policy For Principles Of Consolidation And Equity Accounting Explanatory", "terseLabel": "Principles of consolidation" } } }, "localname": "DescriptionOfAccountingPolicyForPrinciplesOfConsolidationAndEquityAccountingExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "blrx_DescriptionOfAccountingPolicyForWarrantExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for warrants.", "label": "Description Of Accounting Policy For Warrant Explanatory", "verboseLabel": "Warrants" } } }, "localname": "DescriptionOfAccountingPolicyForWarrantExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "blrx_DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of useful life or lease period of right of use assets.", "label": "Description Of Useful Life Or Lease Period Of Right Of Use Assets", "terseLabel": "Estimated useful lives or lease period of right of use assets" } } }, "localname": "DescriptionOfUsefulLifeOrLeasePeriodOfRightOfUseAssets", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "xbrltype": "stringItemType" }, "blrx_DirectPlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Direct Placement [Member]", "label": "Direct Placement [Member]" } } }, "localname": "DirectPlacementMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_DirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Director [Member]", "label": "Directors [Member]", "terseLabel": "Director [Member]" } } }, "localname": "DirectorsMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "blrx_DisallowedDeductionsTaxExemptIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disallowed deductions tax exempt income.", "label": "Disallowed Deductions Tax Exempt Income Abstract", "terseLabel": "Disallowed deductions (tax exempt income):" } } }, "localname": "DisallowedDeductionsTaxExemptIncomeAbstract", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails" ], "xbrltype": "stringItemType" }, "blrx_DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Accounting Judgements And Estimates Explanatory Abstract", "terseLabel": "Disclosure of critical accounting estimates and judgments [Abstract]" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatoryAbstract", "nsuri": "http://biolinerx.com/20221231", "xbrltype": "stringItemType" }, "blrx_DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure detailed information about classification of financial assets and liabilities.", "label": "Disclosure Of Classification Of Financial Assets And Liabilities Explanatory", "terseLabel": "Schedule of Linkage of Monetary Items" } } }, "localname": "DisclosureOfClassificationOfFinancialAssetsAndLiabilitiesExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "blrx_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of commitments and contingent liabilities [Abstract]" } } }, "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesAbstract", "nsuri": "http://biolinerx.com/20221231", "xbrltype": "stringItemType" }, "blrx_DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about accounts payable and accruals.", "label": "Disclosure Of Detailed Information About Accounts Payable And Accruals Explanatory", "terseLabel": "Schedule of Accounts Payable and Accruals" } } }, "localname": "DisclosureOfDetailedInformationAboutAccountsPayableAndAccrualsExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "blrx_DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about basic loss per share.", "label": "Disclosure Of Detailed Information About Basic Loss Per Share Explanatory", "terseLabel": "Schedule of Basic Loss Per Share" } } }, "localname": "DisclosureOfDetailedInformationAboutBasicLossPerShareExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "blrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about cash and cash equivalents.", "label": "Disclosure Of Detailed Information About Cash And Cash Equivalents Explanatory", "terseLabel": "Schedule of Cash And Cash Equivalents" } } }, "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CashAndCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "blrx_DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about concentration of currency risk.", "label": "Disclosure Of Detailed Information About Concentration Of Currency Risk Explanatory", "terseLabel": "Schedule of Concentration of Currency Risk" } } }, "localname": "DisclosureOfDetailedInformationAboutConcentrationOfCurrencyRiskExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "blrx_DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about future repayments of long term bank loan.", "label": "Disclosure Of Detailed Information About Future Repayments Of Long Term Bank Loan Explanatory", "terseLabel": "Schedule of Future Repayments of Long-Term Bank Loan" } } }, "localname": "DisclosureOfDetailedInformationAboutFutureRepaymentsOfLongTermBankLoanExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/Long-termLoansTables" ], "xbrltype": "textBlockItemType" }, "blrx_DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about income and expense.", "label": "Disclosure Of Detailed Information About Income And Expenses Explanatory", "terseLabel": "Schedule of Income and Expenses" } } }, "localname": "DisclosureOfDetailedInformationAboutIncomeAndExpensesExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "blrx_DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about other receivables.", "label": "Disclosure Of Detailed Information About Other Receivables Explanatory", "terseLabel": "Schedule of Other Receivables" } } }, "localname": "DisclosureOfDetailedInformationAboutOtherReceivablesExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "blrx_DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about useful lives for property, plant and equipment.", "label": "Disclosure Of Detailed Information About Useful Life Of Property Plant And Equipment Explanatory", "terseLabel": "Schedule of Depreciation Rates" } } }, "localname": "DisclosureOfDetailedInformationAboutUsefulLifeOfPropertyPlantAndEquipmentExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "blrx_DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about weighted average tax rate applicable to income.", "label": "Disclosure Of Detailed Information About Weighted Average Tax Rate Applicable To Income Explanatory", "terseLabel": "Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income" } } }, "localname": "DisclosureOfDetailedInformationAboutWeightedAverageTaxRateApplicableToIncomeExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeTables" ], "xbrltype": "textBlockItemType" }, "blrx_DisclosureOfGeneralInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of general information [Abstract]" } } }, "localname": "DisclosureOfGeneralInformationAbstract", "nsuri": "http://biolinerx.com/20221231", "xbrltype": "stringItemType" }, "blrx_DisclosureOfIncomeTaxesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Income Taxes [Abstract]", "terseLabel": "Taxes On Income Schedule Of Reconciliation Of Weighted Average Tax Rate Applicable To Income", "verboseLabel": "Taxes On Income" } } }, "localname": "DisclosureOfIncomeTaxesAbstract", "nsuri": "http://biolinerx.com/20221231", "xbrltype": "stringItemType" }, "blrx_DisclosureOfLeasesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "Disclosure Of Leases [Line Items]" } } }, "localname": "DisclosureOfLeasesLineItems", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "blrx_DisclosureOfLeasesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to leases.", "label": "Disclosure Of Leases [Table]" } } }, "localname": "DisclosureOfLeasesTable", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of quantitative information about lease liabilities.", "label": "Disclosure Of Quantitative Information About Lease Liabilities Explanatory", "terseLabel": "Schedule of Lease Liabilities" } } }, "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Quantitative Information About Lease Liabilities [Line Items]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "blrx_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Quantitative Information About Lease Liabilities [Table]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTable", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "blrx_DisclosureOfShortTermBankDepositsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Short Term Bank Deposits Abstract", "terseLabel": "Disclosure of short-term bank deposits [Abstract]" } } }, "localname": "DisclosureOfShortTermBankDepositsAbstract", "nsuri": "http://biolinerx.com/20221231", "xbrltype": "stringItemType" }, "blrx_DisclosureOfSignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of significant accounting policies [Abstract]" } } }, "localname": "DisclosureOfSignificantAccountingPoliciesAbstract", "nsuri": "http://biolinerx.com/20221231", "xbrltype": "stringItemType" }, "blrx_DisclosureOfSupplementaryFinancialStatementInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of supplimentry financial statements information.", "label": "Disclosure of supplementary financial statement information [Abstract]", "terseLabel": "Supplementary Financial Statement Information Schedule Of Other Receivables", "verboseLabel": "Supplementary Financial Statement Information" } } }, "localname": "DisclosureOfSupplementaryFinancialStatementInformationAbstract", "nsuri": "http://biolinerx.com/20221231", "xbrltype": "stringItemType" }, "blrx_DisclosureOfSupplementaryFinancialStatementInformationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplementary financial statement information.", "label": "Disclosure Of Supplementary Financial Statement Information Explanatory", "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION" } } }, "localname": "DisclosureOfSupplementaryFinancialStatementInformationExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformation" ], "xbrltype": "textBlockItemType" }, "blrx_DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information of useful life of right of use assets.", "label": "Disclosure Of Useful Life Of Right Of Use Assets Explanatory", "terseLabel": "Schedule of Useful Life of Right of Use Assets" } } }, "localname": "DisclosureOfUsefulLifeOfRightOfUseAssetsExplanatory", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "blrx_DollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dollar [Member]", "label": "Dollar [Member]" } } }, "localname": "DollarMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "domainItemType" }, "blrx_EmployeesAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees and Directors [Member]", "label": "Employees and Directors [Member]" } } }, "localname": "EmployeesAndDirectorsMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "blrx_EuroLinkedTradePayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Euro-linked trade payables [Member]", "label": "Euro Linked Trade Payables [Member]", "terseLabel": "Euro-linked trade payables [Member]" } } }, "localname": "EuroLinkedTradePayablesMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "blrx_EuroPerDollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Euro Per Dollar [Member]", "label": "Euro Per Dollar Member", "terseLabel": "Euro per $1" } } }, "localname": "EuroPerDollarMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "blrx_ExchangeDifferencesDuringYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excahnge difference in lease liabilities.", "label": "Exchange differences during year", "negatedTerseLabel": "Exchange differences during year", "terseLabel": "Exchange Differences During Year" } } }, "localname": "ExchangeDifferencesDuringYear", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_ExchangeDifferencesOnLeaseLiability": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 60.0, "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for exchange differences on lease liability to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Exchange differences on lease liability", "terseLabel": "Exchange differences on lease liabilities" } } }, "localname": "ExchangeDifferencesOnLeaseLiability", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_ExercisableTermOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercisable term of warrant.", "label": "Exercisable term of warrant" } } }, "localname": "ExercisableTermOfWarrant", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "blrx_ExercisePriceOfShareIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price of shares issued.", "label": "Exercise Price Of Share Issued", "terseLabel": "Exercise price of shares issued" } } }, "localname": "ExercisePriceOfShareIssued", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "blrx_ExercisePriceOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price of warrants.", "label": "Exercise price of warrants" } } }, "localname": "ExercisePriceOfWarrants", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "blrx_ExercisePriceRangeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Up to 10.00 [Member]", "label": "Exercise Price Range Member", "terseLabel": "Up to 0.99 [Member]" } } }, "localname": "ExercisePriceRangeMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "blrx_ExercisePriceRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "10.01-20.00 [Member]", "label": "Exercise Price Range One Member", "terseLabel": "1.00-2.00 [Member]" } } }, "localname": "ExercisePriceRangeOneMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "blrx_ExercisePriceRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "20.01-30.00 [Member]", "label": "Exercise Price Range Two Member", "terseLabel": "2.01-10.00 [Member]" } } }, "localname": "ExercisePriceRangeTwoMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "blrx_FairValueOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Balance as of January 1.", "label": "Fair Value Of Warrants", "periodEndLabel": "Balance as of December 31", "periodStartLabel": "Balance as of January 1" } } }, "localname": "FairValueOfWarrants", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_FirstThreeYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First three years.", "label": "First Three Years [Member]", "terseLabel": "First three years [Member]" } } }, "localname": "FirstThreeYearsMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "blrx_FirstTrancheMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for first tranche.", "label": "First Tranche [Member]", "verboseLabel": "First tranche [Member]" } } }, "localname": "FirstTrancheMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_FivePercentDecreaseEffectOnNetIncomeLossAndEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The effect of a five percent decrease in the given metric on net income (loss) and equity.", "label": "Five Percent Decrease Effect On Net Income Loss And Equity", "terseLabel": "5% decrease effect on net income (loss) and equity" } } }, "localname": "FivePercentDecreaseEffectOnNetIncomeLossAndEquity", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "monetaryItemType" }, "blrx_FivePercentIncreaseEffectOnNetIncomeLossAndEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The effect of a five percent increase in the given metric on net income (loss) and equity.", "label": "Five Percent Increase Effect On Net Income Loss And Equity", "terseLabel": "5% increase effect on net income (loss) and equity" } } }, "localname": "FivePercentIncreaseEffectOnNetIncomeLossAndEquity", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "monetaryItemType" }, "blrx_GainOnRealizationOfLongtermInvestment": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails": { "order": 20.0, "parentTag": "blrx_ProfitLossFromNonOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on realization of long-term investment.", "label": "Gain On Realization Of Longterm Investment", "negatedLabel": "Gain on realization of long-term investment", "terseLabel": "Gain from realization of long-term investment" } } }, "localname": "GainOnRealizationOfLongtermInvestment", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails" ], "xbrltype": "monetaryItemType" }, "blrx_HCWainwrightAndCoLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "H.C. Wainwright & Co., LLC [Member]", "label": "H C Wainwright And Co Llc [Member]", "terseLabel": "H.C. Wainwright & Co., LLC [Member]" } } }, "localname": "HCWainwrightAndCoLlcMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_IfrsStatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ifrs Statement [LineItems]", "label": "Ifrs Statement [Line Items]" } } }, "localname": "IfrsStatementLineItems", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "blrx_IfrsStatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ifrs Statement [Table]", "label": "Ifrs Statement [Table]" } } }, "localname": "IfrsStatementTable", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "blrx_IncomeAndExpensesNotInvolvingCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income And Expenses Not Involving Cash Flows Abstract", "terseLabel": "Income and expenses not involving cash flows:" } } }, "localname": "IncomeAndExpensesNotInvolvingCashFlowsAbstract", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "stringItemType" }, "blrx_IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from amounts recognized through profit and loss.", "label": "Increase Decrease Through Amounts Recognized Through Profit And Loss Arising From Financing Activities", "terseLabel": "Amounts recognized through profit and loss" } } }, "localname": "IncreaseDecreaseThroughAmountsRecognizedThroughProfitAndLossArisingFromFinancingActivities", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows paid.", "label": "Increase Decrease Through Financing Cash Flows Paid Liabilities Arising From Financing Activities", "terseLabel": "Cash flows paid" } } }, "localname": "IncreaseDecreaseThroughFinancingCashFlowsPaidLiabilitiesArisingFromFinancingActivities", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows received.", "label": "Increase Decrease Through Financing Cash Flows Received Liabilities Arising From Financing Activities", "terseLabel": "Cash flows received" } } }, "localname": "IncreaseDecreaseThroughFinancingCashFlowsReceivedLiabilitiesArisingFromFinancingActivities", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_IncreaseDecreaseThroughForfeitedAndExpiredOfOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Employee stock options forfeited and expired.", "label": "Increase Decrease Through Forfeited And Expired Of Options", "terseLabel": "Employee stock options forfeited and expired" } } }, "localname": "IncreaseDecreaseThroughForfeitedAndExpiredOfOptions", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "blrx_IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": { "order": 40.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created.", "label": "Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created" } } }, "localname": "IncreaseInTaxesForTaxLossesAndTimingDifferencesIncurredInReportingYearForWhichDeferredTaxesWereNotCreated", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_InstitutionsCurrentReceivables": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails": { "order": 0.0, "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Institutions other receivables.", "label": "Institutions Current Receivables", "terseLabel": "Government institutions" } } }, "localname": "InstitutionsCurrentReceivables", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_InterestAndExchangeDifferencesOnRestrictedDeposits": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 50.0, "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and exchange differences on restricted deposits.", "label": "Interest And Exchange Differences On Restricted Deposits", "terseLabel": "Warrant issuance costs" } } }, "localname": "InterestAndExchangeDifferencesOnRestrictedDeposits", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_InterestAndExchangeDifferencesOnShortTermDeposits": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 30.0, "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and exchange differences on short-term deposits.", "label": "Interest And Exchange Differences On Short Term Deposits", "terseLabel": "Interest and exchange differences on short-term deposits" } } }, "localname": "InterestAndExchangeDifferencesOnShortTermDeposits", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_InterestAndLinkageDifferencesOnBankLoan": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 10.0, "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and linkage differences on bank loan.", "label": "Interest And Linkage Differences On Bank Loan", "terseLabel": "Interest accrued" } } }, "localname": "InterestAndLinkageDifferencesOnBankLoan", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_InterestExpenseLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest expense on lease liabilities.", "label": "Interest Expense Lease Liabilities", "terseLabel": "Interest expense during year" } } }, "localname": "InterestExpenseLeaseLiabilities", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_InterestRateOnLongTermBankLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate on long term bank loan.", "label": "Interest rate on long term bank loan" } } }, "localname": "InterestRateOnLongTermBankLoan", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "percentItemType" }, "blrx_InterestRateOnShortTermDeposits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate on short-term deposits.", "label": "Interest Rate On Short Term Deposits", "verboseLabel": "Interest rate on short-term deposits" } } }, "localname": "InterestRateOnShortTermDeposits", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails" ], "xbrltype": "percentItemType" }, "blrx_InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate on short-term deposits.", "label": "Interest Rate On Short Term Deposits Includes Cash And Cash Equivalents", "terseLabel": "Interest rate on short-term deposits" } } }, "localname": "InterestRateOnShortTermDepositsIncludesCashAndCashEquivalents", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "blrx_InvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investors [Member]", "label": "Investors [Member]" } } }, "localname": "InvestorsMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_IssuancesOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuances.", "label": "Issuances Of Warrants", "terseLabel": "Issuances" } } }, "localname": "IssuancesOfWarrants", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_IssuedAndPaidUpShareCapitalValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issued and paid up share capital.", "label": "Issued And Paid Up Share Capital Value", "verboseLabel": "Issued and paid-up share capital" } } }, "localname": "IssuedAndPaidUpShareCapitalValue", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "blrx_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory equipment [Member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" ], "xbrltype": "domainItemType" }, "blrx_LawsuitClaimAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "lawsuit claim amount", "label": "Lawsuit Claim Amount", "verboseLabel": "Lawsuit claim amount" } } }, "localname": "LawsuitClaimAmount", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_LeaseAgreementMonthlyFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease agreement monthly fee.", "label": "Lease agreement monthly fee" } } }, "localname": "LeaseAgreementMonthlyFee", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_LeasePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Period.", "label": "Lease Period" } } }, "localname": "LeasePeriod", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "blrx_LoanAgreementWithKreosCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Agreement With Kreos Capital [Member]", "label": "Loan Agreement With Kreos Capital [Member]" } } }, "localname": "LoanAgreementWithKreosCapitalMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_LoanTakenForPaymentOfAgreementValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents amount of loan taken for payment of agreement value.", "label": "Loan Taken For Payment Of Agreement Value", "verboseLabel": "Loan taken from Kreos Capital for the payment" } } }, "localname": "LoanTakenForPaymentOfAgreementValue", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_MarketSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Market price of ordinary shares.", "label": "Market Share Price", "terseLabel": "Market price of ordinary shares" } } }, "localname": "MarketSharePrice", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "blrx_MarketingExpenses": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": { "order": 10.0, "parentTag": "ifrs-full_SalesAndMarketingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Marketing Expenses.", "label": "Marketing Expenses", "terseLabel": "Marketing" } } }, "localname": "MarketingExpenses", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_MaturitiesOfShortTermDeposits": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maturities of short-term deposits.", "label": "Maturities Of Short Term Deposits", "negatedLabel": "Maturities of short-term deposits" } } }, "localname": "MaturitiesOfShortTermDeposits", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_MaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturity date of warrant.", "label": "Maturity Date", "terseLabel": "Maturity date of warrant" } } }, "localname": "MaturityDate", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "blrx_MaximumFutureMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represent the maximum future milestone payments.", "label": "Maximum Future Milestone Payments", "terseLabel": "Maximum future milestone payments" } } }, "localname": "MaximumFutureMilestonePayments", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_NetAssetValueOfLinkageMonetaryItems": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net asset value of linkage monetary items.", "label": "Net Asset Value Of Linkage Monetary Items", "totalLabel": "Net asset value", "verboseLabel": "Net asset value" } } }, "localname": "NetAssetValueOfLinkageMonetaryItems", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_NetBookValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net book value.", "label": "Net Book Value [Member]", "terseLabel": "Net book value [Member]" } } }, "localname": "NetBookValueMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" ], "xbrltype": "domainItemType" }, "blrx_NetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net [Member]", "label": "Net Member", "terseLabel": "Total [Member]" } } }, "localname": "NetMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "blrx_NisLinkedBalancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NIS-linked balances [Member]", "label": "Nis Linked Balances Member", "terseLabel": "NIS-linked balances [Member]" } } }, "localname": "NisLinkedBalancesMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "blrx_NisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NIS [Member]", "label": "NIS [Member]" } } }, "localname": "NisMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "domainItemType" }, "blrx_NisPerDollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nis Per Dollar [Member]", "label": "Nis Per Dollar Member", "terseLabel": "NIS per $1" } } }, "localname": "NisPerDollarMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "blrx_NonOperatingExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-operating expense incurred.", "label": "Non operating expense" } } }, "localname": "NonOperatingExpense", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_NumberOfOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options.", "label": "Number Of Options Abstract", "terseLabel": "Number of options" } } }, "localname": "NumberOfOptionsAbstract", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "blrx_NumberOfOrdinarySharesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of ordinary shares.", "label": "Number of Ordinary Shares Abstract", "terseLabel": "Number of Ordinary Shares" } } }, "localname": "NumberOfOrdinarySharesAbstract", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails" ], "xbrltype": "stringItemType" }, "blrx_NumberOfPremises": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents number of premises.", "label": "Number Of Premises", "verboseLabel": "Number of premises" } } }, "localname": "NumberOfPremises", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails" ], "xbrltype": "decimalItemType" }, "blrx_OpenPurchaseOrderCommitments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total outstanding open purchase order commitments.", "label": "Open Purchase Order Commitments", "terseLabel": "Company's outstanding open purchase order commitments" } } }, "localname": "OpenPurchaseOrderCommitments", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_OtherComprehensiveIncomeLossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other comprehensive income loss [Member]", "label": "Other Comprehensive Income Loss [Member]", "terseLabel": "Other comprehensive loss [Member]" } } }, "localname": "OtherComprehensiveIncomeLossMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "blrx_OtherCurrenciesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OrbiMed Advisors LLC [Member]", "label": "Other Currencies [Member]", "terseLabel": "GBP and other [Member]" } } }, "localname": "OtherCurrenciesMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "domainItemType" }, "blrx_OtherNonoperatingIncomeExpenses": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails": { "order": 30.0, "parentTag": "blrx_ProfitLossFromNonOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other nonoperating income (expense).", "label": "Other Nonoperating Income Expenses", "verboseLabel": "Other" } } }, "localname": "OtherNonoperatingIncomeExpenses", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails" ], "xbrltype": "monetaryItemType" }, "blrx_OtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables.", "label": "Other Payables Abstract", "terseLabel": "Other:" } } }, "localname": "OtherPayablesAbstract", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" ], "xbrltype": "stringItemType" }, "blrx_OtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables [Member]", "label": "Other Payables [Member]", "terseLabel": "Other payables [Member]" } } }, "localname": "OtherPayablesMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "blrx_OtherReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other receivables [Member]", "label": "Other Receivables [Member]", "terseLabel": "Other receivables [Member]" } } }, "localname": "OtherReceivablesMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "blrx_Others": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails": { "order": 10.0, "parentTag": "ifrs-full_OtherCurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of other receivables.", "label": "Others", "verboseLabel": "Other" } } }, "localname": "Others", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_PaymentsLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments of lease liabilities.", "label": "Payments Lease Liabilities", "negatedLabel": "Payments during year" } } }, "localname": "PaymentsLeaseLiabilities", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_PayrollAndRelatedExpenses": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": { "order": 0.0, "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payroll and related expenses.", "label": "Payroll And Related Expenses", "terseLabel": "Payroll and related expenses" } } }, "localname": "PayrollAndRelatedExpenses", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_PercentageIncreaseDecreaseInExchangeRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage increase (decrease) in exchange rate.", "label": "Percentage Increase Decrease In Exchange Rate", "terseLabel": "Percentage increase (decrease) in USD exchange rate" } } }, "localname": "PercentageIncreaseDecreaseInExchangeRate", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails" ], "xbrltype": "percentItemType" }, "blrx_PercentageIncreasePrecedingLeasePaymentAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Increase preceding lease payment amount.", "label": "Percentage Increase preceding lease payment amount" } } }, "localname": "PercentageIncreasePrecedingLeasePaymentAmount", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "blrx_PercentageOfAnnualInterestOfCashFees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents percentage of annual interest of cash fees.", "label": "Percentage Of Annual Interest Of Cash Fees", "verboseLabel": "Percentage of annual interest of cash fees" } } }, "localname": "PercentageOfAnnualInterestOfCashFees", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "percentItemType" }, "blrx_PercentageOfCommissionOnSalesAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of commission on sales agreement.", "label": "Percentage of commission on sales agreement" } } }, "localname": "PercentageOfCommissionOnSalesAgreement", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "blrx_PercentageOfNetConsiderationReceivedFromLicensee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of net consideration received from the licensee.", "label": "Percentage of net consideration received from the licensee" } } }, "localname": "PercentageOfNetConsiderationReceivedFromLicensee", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "blrx_PercentageOfPaymentToBeMade": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of payment to be made.", "label": "Percentage Of Payment To Be Made", "verboseLabel": "Percentage of payment to be made" } } }, "localname": "PercentageOfPaymentToBeMade", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "blrx_PerformanceSharesUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Shares Unit [Member]", "label": "Performance Shares Unit [Member]" } } }, "localname": "PerformanceSharesUnitMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_PlacementAgentsDesigneesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Placement Agent's Designees [Member]", "label": "Placement Agent's Designees [Member]" } } }, "localname": "PlacementAgentsDesigneesMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_ProceedsFromIssuanceOfInitialPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from public offering.", "label": "Proceeds From Issuance Of Initial Public Offering", "terseLabel": "Proceeds from public offering, gross" } } }, "localname": "ProceedsFromIssuanceOfInitialPublicOffering", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_ProceedsFromIssuanceOfInitialPublicOfferingNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from public offering, net.", "label": "Proceeds From Issuance Of Initial Public Offering Net", "terseLabel": "Proceeds from public offering, net" } } }, "localname": "ProceedsFromIssuanceOfInitialPublicOfferingNet", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_ProceedsFromWarrantIssue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from warrant issue.", "label": "Proceeds From Warrant Issue", "terseLabel": "Proceeds from warrant issue, net" } } }, "localname": "ProceedsFromWarrantIssue", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_ProfessionalFee": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 40.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fee expense related to professional.", "label": "Professional Fee", "terseLabel": "Professional fees" } } }, "localname": "ProfessionalFee", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_ProfitLossFromNonOperatingActivities": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 10.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 }, "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non operating profit (loss) from operating activities of the entity.", "label": "Profit Loss From Non Operating Activities", "terseLabel": "NON-OPERATING INCOME (EXPENSES), NET", "totalLabel": "Non-operating income, net" } } }, "localname": "ProfitLossFromNonOperatingActivities", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails" ], "xbrltype": "monetaryItemType" }, "blrx_PurchaseAgreementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase agreement period.", "label": "Purchase agreement period" } } }, "localname": "PurchaseAgreementPeriod", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "blrx_RemainingAuthorizedUnissuedOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining authorized unissued ordinary shares.", "label": "Remaining authorized unissued ordinary shares" } } }, "localname": "RemainingAuthorizedUnissuedOrdinaryShares", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "blrx_RemainingUnrecognizedDeferredCompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Remaining unrecognized deferred compensation expense.", "label": "Remaining unrecognized deferred compensation expense" } } }, "localname": "RemainingUnrecognizedDeferredCompensationExpense", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The revised weighted average exercise price of share options exercised in a share-based payment arrangement.", "label": "Revised Weighted Average Exercise Price Of Share Options Exercised In Share Based Payment Arrangement 2019", "verboseLabel": "Revised weighted average exercise price" } } }, "localname": "RevisedWeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement2019", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "blrx_RoyaltiesOnSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties on sale.", "label": "Royalties on sale" } } }, "localname": "RoyaltiesOnSale", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "blrx_RoyaltiesPaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the royalties payment percentage.", "label": "Royalties Payment Percentage", "terseLabel": "Royalties payment percentage" } } }, "localname": "RoyaltiesPaymentPercentage", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "blrx_RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the royalties payment percentage if the company independently sell products.", "label": "Royalties Payment Percentage If Company Independently Sell Products", "terseLabel": "Royalties payment percentage if the company independently sell products" } } }, "localname": "RoyaltiesPaymentPercentageIfCompanyIndependentlySellProducts", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "blrx_RoyaltiesReceivedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties received percentage.", "label": "Royalties received percentage" } } }, "localname": "RoyaltiesReceivedPercentage", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "blrx_SaleOfStockNumberOfSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of stock.", "label": "Sale Of Stock Number Of Shares Issued", "terseLabel": "Sale of stock" } } }, "localname": "SaleOfStockNumberOfSharesIssued", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "blrx_SalesAndMarketingPayrollExpense": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": { "order": 0.0, "parentTag": "ifrs-full_SalesAndMarketingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payroll and related expenses, including vehicles.", "label": "Sales And Marketing Payroll Expense", "verboseLabel": "Payroll and related expenses" } } }, "localname": "SalesAndMarketingPayrollExpense", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_SecondTrancheMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for second tranche.", "label": "Second Tranche [Member]", "verboseLabel": "Second tranche [Member]" } } }, "localname": "SecondTrancheMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_SeniorManagementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Management [Member]", "label": "Senior Management [Member]" } } }, "localname": "SeniorManagementMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "blrx_SeriesAWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A [Member]", "label": "Series A Warrants [Member]" } } }, "localname": "SeriesAWarrantsMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_SeriesBWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B [Member]", "label": "Series B Warrant [Member]", "terseLabel": "Series B [Member]" } } }, "localname": "SeriesBWarrantMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_SeventhYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seventh year [Member]", "label": "Seventh Year [Member]", "terseLabel": "Seventh year [Member]" } } }, "localname": "SeventhYearMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "blrx_ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": { "order": 10.0, "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represent the amount of share based compensation related to general and administrative expenses.", "label": "Share Based Compensation Related To General And Administrative Expenses", "terseLabel": "Share based compensation" } } }, "localname": "ShareBasedCompensationRelatedToGeneralAndAdministrativeExpenses", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "blrx_ShareBasedCompensationRelatedToResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 20.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represent the amount of share based compensation related to research and development.", "label": "Share Based Compensation Related To Research And Development", "terseLabel": "Share based compensation" } } }, "localname": "ShareBasedCompensationRelatedToResearchAndDevelopment", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "blrx_ShareIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2003 Plan [Member]", "label": "Share Incentive Plan Member", "terseLabel": "2003 Plan [Member]" } } }, "localname": "ShareIncentivePlanMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_ShareIssuedAsAdditionalCommitmentFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share issued as additional commitment fee.", "label": "Share issued as additional commitment fee" } } }, "localname": "ShareIssuedAsAdditionalCommitmentFee", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "blrx_ShareIssuedOfPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwritten public offering.", "label": "Share Issued Of Public Offering", "terseLabel": "Underwritten public offering" } } }, "localname": "ShareIssuedOfPublicOffering", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "blrx_ShareIssuedToPurchaseWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued to purchase warrant.", "label": "Share Issued To Purchase Warrant", "terseLabel": "Shares issued to purchase warrant" } } }, "localname": "ShareIssuedToPurchaseWarrant", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "blrx_SharePremiumResultingFromExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share premium resulting from exercise of warrants.", "label": "Share Premium Resulting From Exercise Of Warrants", "terseLabel": "Share premium resulting from exercise of warrants" } } }, "localname": "SharePremiumResultingFromExerciseOfWarrants", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_SharePurchaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share purchase agreement.", "label": "Share purchase agreement" } } }, "localname": "SharePurchaseAgreement", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_SharePurchaseAgreementShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share purchase agreement, shares.", "label": "Share purchase agreement, shares" } } }, "localname": "SharePurchaseAgreementShares", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "blrx_SharesIssuedRegisteredDirectOfferings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Registered direct offerings sales.", "label": "Shares Issued Registered Direct Offerings", "terseLabel": "Registered direct offerings sales" } } }, "localname": "SharesIssuedRegisteredDirectOfferings", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "blrx_StockIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public offering price.", "label": "Stock Issued Price Per Share", "terseLabel": "Public offering price" } } }, "localname": "StockIssuedPricePerShare", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "blrx_SupplementalInformationOnInterestPaidInCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Supplemental information on interest paid in cash.", "label": "Supplemental Information On Interest Paid In Cash", "terseLabel": "Supplemental information on interest paid in cash" } } }, "localname": "SupplementalInformationOnInterestPaidInCash", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Supplementary information on Changes In Right-of-use Asset And Lease Liabilities", "label": "Supplementary Information On Changes In Right Of Use Asset And Lease Liabilities", "verboseLabel": "Changes in right-of-use asset and lease liabilities" } } }, "localname": "SupplementaryInformationOnChangesInRightOfUseAssetAndLeaseLiabilities", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_SupplementaryInformationOnFairValueOfExercisedWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represent the amount of Supplementary information on Fair Value Of Exercised Warrants", "label": "Supplementary Information On Fair Value Of Exercised Warrants", "verboseLabel": "Fair value of exercised warrants (portion related to accumulated fair value adjustments)" } } }, "localname": "SupplementaryInformationOnFairValueOfExercisedWarrants", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_SupplementaryInformationOnInterestReceivedInCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Supplementary information on interest received in cash.", "label": "Supplementary Information On Interest Received In Cash", "terseLabel": "Supplemental information on interest received in cash" } } }, "localname": "SupplementaryInformationOnInterestReceivedInCash", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplementary Information On Investing And Financing Activities Not Involving Cash Flows Abstract", "terseLabel": "Supplementary information on investing and financing activities not involving cash flows:" } } }, "localname": "SupplementaryInformationOnInvestingAndFinancingActivitiesNotInvolvingCashFlowsAbstract", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "stringItemType" }, "blrx_SupplementaryInformationOnPurchaseOfPropertyAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represent the amount of Supplementary Information On Purchase Of Property And Equipment", "label": "Supplementary Information On Purchase Of Property And Equipment", "verboseLabel": "Purchase of property and equipment" } } }, "localname": "SupplementaryInformationOnPurchaseOfPropertyAndEquipment", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_SupplementaryInformationOnWarrantIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represent the amount of Supplementary Information On Warrant issuance costs", "label": "Supplementary Information On Warrant Issuance Costs", "verboseLabel": "Warrant issuance costs" } } }, "localname": "SupplementaryInformationOnWarrantIssuanceCosts", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_SupplementaryNonCashInvestment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Supplementary non-cash investment.", "label": "Supplementary Non Cash Investment", "terseLabel": "Supplemental information on non-cash transactions" } } }, "localname": "SupplementaryNonCashInvestment", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": { "order": 10.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to gains on adjustments of warrants to fair value, that are exempt from taxation.", "label": "Tax Effect Of Gain On Adjustment Of Warrants Fair Value Exempt From Taxation", "terseLabel": "Loss (gain) on adjustment of warrants to fair value" } } }, "localname": "TaxEffectOfGainOnAdjustmentOfWarrantsFairValueExemptFromTaxation", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_TaxEffectOfShareBasedCompensationExemptFromTaxation": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": { "order": 20.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to share-based compensation that are exempt from taxation.", "label": "Tax Effect Of Share Based Compensation Exempt From Taxation", "verboseLabel": "Share-based compensation" } } }, "localname": "TaxEffectOfShareBasedCompensationExemptFromTaxation", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_TaxLossCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax loss carryforwards.", "label": "Tax Loss Carryforwards", "terseLabel": "Tax loss carryforwards" } } }, "localname": "TaxLossCarryforwards", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_TenPercentDecreaseEffectOnNetIncomeLossAndEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The effect of a ten percent decrease in the given metric on net income (loss) and equity.", "label": "Ten Percent Decrease Effect On Net Income Loss And Equity", "terseLabel": "10% decrease effect on net income (loss) and equity" } } }, "localname": "TenPercentDecreaseEffectOnNetIncomeLossAndEquity", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "monetaryItemType" }, "blrx_TenPercentIncreaseEffectOnNetIncomeLossAndEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The effect of a ten percent increase in the given metric on net income (loss) and equity.", "label": "Ten Percent Increase Effect On Net Income Loss And Equity", "terseLabel": "10% increase effect on net income (loss) and equity" } } }, "localname": "TenPercentIncreaseEffectOnNetIncomeLossAndEquity", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "monetaryItemType" }, "blrx_ThreeSubsequentYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three subsequent year [Member]", "label": "Three Subsequent Years Member", "terseLabel": "Three subsequent years [Member]" } } }, "localname": "ThreeSubsequentYearsMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "blrx_TotalChangeInOperatingAssetAndLiability": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 10.0, "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total Change in operating asset and liability.", "label": "Total Change In Operating Asset And Liability", "totalLabel": "Total Change in operating asset and liability" } } }, "localname": "TotalChangeInOperatingAssetAndLiability", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 0.0, "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total income and expense not involving cash flows.", "label": "Total Income And Expense Not Involving Cash Flows", "totalLabel": "Total income and expense not involving cash flows" } } }, "localname": "TotalIncomeAndExpenseNotInvolvingCashFlows", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "blrx_TradeAndOtherPayablesToForeignTradeSuppliers": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": { "order": 0.0, "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of payment due to foreign suppliers for goods and services used in the entity's business.", "label": "Trade And Other Payables To Foreign Trade Suppliers", "terseLabel": "Overseas" } } }, "localname": "TradeAndOtherPayablesToForeignTradeSuppliers", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_TradeAndOtherPayablesToLocalTradeSuppliers": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": { "order": 10.0, "parentTag": "ifrs-full_TradeAndOtherPayablesToTradeSuppliers", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of payment due to local suppliers for goods and services used in the entity's business.", "label": "Trade And Other Payables To Local Trade Suppliers", "terseLabel": "In Israel" } } }, "localname": "TradeAndOtherPayablesToLocalTradeSuppliers", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_TradePayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade payables.", "label": "Trade Payables Abstract", "terseLabel": "Trade:" } } }, "localname": "TradePayablesAbstract", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" ], "xbrltype": "stringItemType" }, "blrx_TradePayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade payables [Member]", "label": "Trade Payables [Member]", "terseLabel": "Trade payables [Member]" } } }, "localname": "TradePayablesMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "blrx_TrancheAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.", "label": "Tranche [Axis]" } } }, "localname": "TrancheAxis", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "stringItemType" }, "blrx_TrancheDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for tranche.", "label": "Tranche [Domain]" } } }, "localname": "TrancheDomain", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_UnderwaterEmployeeStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwater Employee Stock Options [Member]", "label": "Underwater Employee Stock Options [Member]" } } }, "localname": "UnderwaterEmployeeStockOptionsMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_UniformTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Uniform tax rate.", "label": "Uniform Tax Rate", "terseLabel": "Uniform tax rate" } } }, "localname": "UniformTaxRate", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails" ], "xbrltype": "percentItemType" }, "blrx_ValueOfServicesRecorded": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of services recorded.", "label": "Value of services recorded" } } }, "localname": "ValueOfServicesRecorded", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "blrx_WarrantFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Four [Member]", "label": "Warrant Four [Member]", "verboseLabel": "Warrant [Member]" } } }, "localname": "WarrantFourMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_WarrantOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant [Member]", "label": "Warrant One Member", "terseLabel": "Warrant [Member]" } } }, "localname": "WarrantOneMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_WarrantThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Three [Member]", "label": "Warrant Three [Member]", "verboseLabel": "Warrant [Member]" } } }, "localname": "WarrantThreeMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_WarrantTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant One[Member]", "label": "Warrant Two [Member]", "verboseLabel": "Warrant [Member]" } } }, "localname": "WarrantTwoMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "blrx_Warrants": { "auth_ref": [], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 10.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The non-current portion of warrants.", "label": "Warrants" } } }, "localname": "Warrants", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "blrx_WarrantsExercises": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exercises.", "label": "Warrants Exercises", "terseLabel": "Exercises" } } }, "localname": "WarrantsExercises", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "blrx_WarrantsExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants expiration period.", "label": "Warrants expiration period" } } }, "localname": "WarrantsExpirationPeriod", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "blrx_WarrantsIssuedToPurchaseShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants issued to purchase shares.", "label": "Warrants issued to purchase shares" } } }, "localname": "WarrantsIssuedToPurchaseShares", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "blrx_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Member]", "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" ], "xbrltype": "domainItemType" }, "blrx_WeightedAverageExercisePriceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price.", "label": "Weighted Average Exercise Price Abstract", "terseLabel": "Weighted average exercise price (in NIS)" } } }, "localname": "WeightedAverageExercisePriceAbstract", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "blrx_WithholdingApplicableTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The applicable withholding income tax rate.", "label": "Withholding Applicable Tax Rate", "terseLabel": "Withholding income tax rate" } } }, "localname": "WithholdingApplicableTaxRate", "nsuri": "http://biolinerx.com/20221231", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails" ], "xbrltype": "percentItemType" }, "country_IL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ISRAEL", "verboseLabel": "Israel [Member]" } } }, "localname": "IL", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails", "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r215", "r216", "r217" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r215", "r216", "r217" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r215", "r216", "r217" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r216", "r217" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelEmailAddress": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Email address of contact personnel.", "label": "Contact Personnel Email Address" } } }, "localname": "ContactPersonnelEmailAddress", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelFaxNumber": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Fax Number of contact personnel.", "label": "Contact Personnel Fax Number" } } }, "localname": "ContactPersonnelFaxNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r215", "r216", "r217" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity's Reporting Status Current" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity a Voluntary Filer" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity a Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r215", "r216", "r217" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biolinerx.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "ifrs-full_AccountingProfit": { "auth_ref": [ "r28", "r29" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Loss before taxes", "verboseLabel": "Loss before taxes" } } }, "localname": "AccountingProfit", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "auth_ref": [ "r32", "r37", "r60", "r69", "r72" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Accumulated depreciation and impairment [Member]" } } }, "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "auth_ref": [ "r37", "r232", "r235", "r237", "r238" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Accumulated depreciation [member]", "verboseLabel": "Accumulated depreciation and amortisation [member]" } } }, "localname": "AccumulatedDepreciationAndAmortisationMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncome": { "auth_ref": [ "r227" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 40.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "verboseLabel": "Additions during year" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Additions during year" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsToRightofuseAssets": { "auth_ref": [ "r103" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Additions to right-of-use assets", "verboseLabel": "Additions during year" } } }, "localname": "AdditionsToRightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "auth_ref": [ "r242" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 0.0, "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } }, "en-us": { "role": { "label": "Depreciation and amortization" } } }, "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "auth_ref": [ "r242" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 40.0, "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Fair value adjustments of warrants" } } }, "localname": "AdjustmentsForFairValueGainsLosses", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "auth_ref": [ "r241" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 0.0, "parentTag": "blrx_TotalChangeInOperatingAssetAndLiability", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Increase (decrease) in accounts payable and accruals" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLoss": { "auth_ref": [ "r75" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments required to reflect net cash used in operating activities (see appendix below)", "totalLabel": "Total Adjustments required to reflect net cash used in operating activities", "verboseLabel": "Adjustments required to reflect net cash used in operating activities (see appendix below)" } } }, "localname": "AdjustmentsForReconcileProfitLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r242" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 70.0, "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "verboseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "auth_ref": [ "r189", "r242" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 20.0, "parentTag": "blrx_TotalIncomeAndExpenseNotInvolvingCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Exchange differences on cash and cash equivalents" } } }, "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r11", "r101", "r107", "r108", "r131", "r156", "r157", "r158", "r163", "r178", "r202", "r203" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails", "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "auth_ref": [ "r39", "r96" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } }, "en-us": { "role": { "label": "All levels of fair value hierarchy [member]" } } }, "localname": "AllLevelsOfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount incurred by the entity for provision of key management personnel services that are provided by a separate management entity. [Refer: Key management personnel of entity or parent [member]; Separate management entities [member]]" } }, "en-us": { "role": { "label": "Compensation and benefits to management, including benefit component of equity instrument grants" } } }, "localname": "AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r29" ], "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Corporate tax rate", "verboseLabel": "Loss before taxes (Percentage)" } } }, "localname": "ApplicableTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails", "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r9", "r95", "r96", "r97", "r149", "r151" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets [Default Label]", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets", "verboseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r51", "r52" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "LOSS PER ORDINARY SHARE \u2013 BASIC", "verboseLabel": "Basic and diluted loss per ordinary share" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r100", "r120", "r158", "r193", "r195", "r245" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom of range [member]", "verboseLabel": "Bottom of range [member]" } } }, "localname": "BottomOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails", "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails", "http://biolinerx.com/role/Long-termLoansNarrativeDetails", "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BusinessCombinationsAxis": { "auth_ref": [ "r126" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Business combinations [Axis]", "verboseLabel": "Business combinations [axis]" } } }, "localname": "BusinessCombinationsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CapitalReserve": { "auth_ref": [ "r227" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 30.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the capital reserves." } }, "en-us": { "role": { "label": "Capital reserve" } } }, "localname": "CapitalReserve", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CapitalReserveMember": { "auth_ref": [ "r224" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing capital reserves." } }, "en-us": { "role": { "label": "Capital reserve [Member]" } } }, "localname": "CapitalReserveMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "auth_ref": [ "r32", "r35", "r60", "r63", "r68", "r69", "r70", "r71", "r72", "r127", "r136", "r137", "r248", "r249" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis]", "verboseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountMember": { "auth_ref": [ "r35", "r63", "r68", "r70", "r71", "r127", "r136", "r137", "r209", "r212" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "localname": "CarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r243" ], "calculation": { "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails": { "order": 0.0, "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash on hand and in bank" } } }, "localname": "Cash", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r8", "r78", "r90" ], "calculation": { "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF YEAR", "periodStartLabel": "CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR", "totalLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://biolinerx.com/role/ConsolidatedCashFlowStatements", "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "auth_ref": [ "r239" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } }, "en-us": { "role": { "label": "Investments in short-term deposits" } } }, "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r73", "r80" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 20.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS - FINANCING ACTIVITIES" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r73", "r80" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 10.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS - INVESTING ACTIVITIES" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r73", "r80" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 0.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS - OPERATING ACTIVITIES" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "stringItemType" }, "ifrs-full_CashTransferred": { "auth_ref": [ "r124" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Cash transferred", "terseLabel": "Cash consideration" } } }, "localname": "CashTransferred", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r47" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [Axis]", "verboseLabel": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHANGES IN" } } }, "localname": "ChangesInEquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes during the year:" } } }, "localname": "ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember": { "auth_ref": [ "r173" ], "lang": { "en": { "role": { "documentation": "This member stands for changes in tax rates or tax laws enacted or announced." } }, "en-us": { "role": { "label": "Changes in tax rates or tax laws enacted or announced [Member]" } } }, "localname": "ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfAssetsAxis": { "auth_ref": [ "r56", "r57", "r98", "r105" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of assets [axis]" } } }, "localname": "ClassesOfAssetsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails", "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails", "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsMember": { "auth_ref": [ "r56", "r98", "r105" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } }, "en-us": { "role": { "label": "Assets [member]" } } }, "localname": "ClassesOfAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails", "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails", "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "auth_ref": [ "r136", "r138", "r139", "r140" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial instruments [Axis]", "verboseLabel": "Classes of financial instruments [axis]" } } }, "localname": "ClassesOfFinancialInstrumentsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "auth_ref": [ "r136", "r138", "r139", "r140" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial instruments, class [member]" } } }, "localname": "ClassesOfFinancialInstrumentsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "auth_ref": [ "r64" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [Axis]", "verboseLabel": "Classes of intangible assets other than goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails", "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of property, plant and equipment [Axis]", "verboseLabel": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r18" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r18" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClosingForeignExchangeRate": { "auth_ref": [ "r225" ], "lang": { "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } }, "en-us": { "role": { "label": "Exchange rate per dollar" } } }, "localname": "ClosingForeignExchangeRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_CommunicationExpense": { "auth_ref": [ "r225" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 30.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from communication." } }, "en-us": { "role": { "label": "Lab, occupancy and telephone" } } }, "localname": "CommunicationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_ComputerEquipmentMember": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Computers and communications equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ComputerSoftwareMember": { "auth_ref": [ "r181" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Computer software [Member]" } } }, "localname": "ComputerSoftwareMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CreditExposure": { "auth_ref": [ "r208", "r210", "r211" ], "lang": { "en": { "role": { "documentation": "The amount of exposure to loss resulting from credit risk. [Refer: Credit risk [member]]" } }, "en-us": { "role": { "label": "Line of credit" } } }, "localname": "CreditExposure", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CreditRiskMember": { "auth_ref": [ "r159", "r160", "r161", "r200" ], "lang": { "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Credit risk [member]" } } }, "localname": "CreditRiskMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [ "r227" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": { "order": 20.0, "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]" } }, "en-us": { "role": { "label": "Accrued expenses" } } }, "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r12", "r85", "r191" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS", "verboseLabel": "Current assets:" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "auth_ref": [ "r227" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Current maturities of long-term loans", "negatedLabel": "Less current maturities", "verboseLabel": "Current maturities of long-term loans" } } }, "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r102" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 30.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Lease liabilities", "verboseLabel": "Current lease liabilities" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r13", "r87", "r191" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES", "verboseLabel": "Current liabilities:" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPrepaidExpenses": { "auth_ref": [ "r225" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 20.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } }, "en-us": { "role": { "label": "Prepaid expenses" } } }, "localname": "CurrentPrepaidExpenses", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentProvisionsForEmployeeBenefits": { "auth_ref": [ "r14" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": { "order": 40.0, "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]" } }, "en-us": { "role": { "label": "Accrual for vacation and recreation pay" } } }, "localname": "CurrentProvisionsForEmployeeBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationAndAmortisationExpense": { "auth_ref": [ "r0", "r25", "r91", "r147", "r153", "r166" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 50.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation and amortisation expense", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationExpense": { "auth_ref": [ "r225" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": { "order": 40.0, "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation" } } }, "localname": "DepreciationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for borrowings. [Refer: Borrowings]\nEffective 2023-01-01: The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings" } } }, "localname": "DescriptionOfAccountingPolicyForBorrowingsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]\nEffective 2023-01-01: The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Deferred taxes" } } }, "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for earnings per share.\nEffective 2023-01-01: The description of the entity's material accounting policy information for earnings per share." } }, "en-us": { "role": { "label": "Loss per share" } } }, "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.\nEffective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee benefits" } } }, "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation." } }, "en-us": { "role": { "label": "Functional and reporting currency" } } }, "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Impairment of non-amortized non-financial assets", "verboseLabel": "Impairment of non-financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]\nEffective 2023-01-01: The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets" } } }, "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for issued capital. [Refer: Issued capital]\nEffective 2023-01-01: The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Share capital" } } }, "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.\nEffective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } }, "en-us": { "role": { "label": "Leases" } } }, "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]\nEffective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property and equipment" } } }, "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]\nEffective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Revenue from contracts with customers" } } }, "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]\nEffective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Research and development expenses" } } }, "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r246", "r247" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for trade and other payables. [Refer: Trade and other payables]\nEffective 2023-01-01: The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Trade payables" } } }, "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "auth_ref": [ "r79" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Cash equivalents and short-term bank deposits" } } }, "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r122" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Expected volatility (%)", "verboseLabel": "Average standard deviation" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "auth_ref": [ "r122" ], "lang": { "en": { "role": { "documentation": "The option life of share options granted." } }, "en-us": { "role": { "label": "Expected life of options (in years)" } } }, "localname": "DescriptionOfOptionLifeShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements": { "auth_ref": [ "r164" ], "lang": { "en": { "role": { "documentation": "The description of accounting policies relevant to an understanding of financial statements, which the entity does not separately disclose." } }, "en-us": { "role": { "label": "Basis of presentation" } } }, "localname": "DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r122" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Risk-free interest rate (%)", "verboseLabel": "Risk-free interest rate" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r59" ], "lang": { "en": { "role": { "documentation": "Description of useful life used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Estimated useful lives of intangible assets (In years)" } } }, "localname": "DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment": { "auth_ref": [ "r31" ], "lang": { "en": { "role": { "documentation": "Description of useful life used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation rates (in %)" } } }, "localname": "DescriptionOfUsefulLifePropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement": { "auth_ref": [ "r112" ], "lang": { "en": { "role": { "documentation": "The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Option vested and exercised" } } }, "localname": "DescriptionOfVestingRequirementsForSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r51", "r52" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "LOSS PER ORDINARY SHARE \u2013 DILUTED" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "auth_ref": [ "r222" ], "lang": { "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CriticalAccountingEstimatesAndJudgments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory": { "auth_ref": [ "r106" ], "lang": { "en": { "role": { "documentation": "The disclosure of additional information about leasing activities of a lessee." } }, "en-us": { "role": { "label": "Schedule of Composition of Lease Liabilities" } } }, "localname": "DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory": { "auth_ref": [ "r46" ], "lang": { "en": { "role": { "documentation": "The disclosure of amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities. [Refer: Key management personnel of entity or parent [member]; Separate management entities [member]]" } }, "en-us": { "role": { "label": "Schedule of Key Management Compensation" } } }, "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]" } } }, "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable": { "auth_ref": [ "r46" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities." } }, "en-us": { "role": { "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table]" } } }, "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]" } } }, "localname": "DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more, and more than, twelve months after reporting date." } }, "en-us": { "role": { "label": "Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table]" } } }, "localname": "DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "auth_ref": [ "r222" ], "lang": { "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "LONG-TERM LOANS" } } }, "localname": "DisclosureOfBorrowingsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/Long-termLoans" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r222" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "CASH AND CASH EQUIVALENTS" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CashAndCashEquivalents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [abstract]" } } }, "localname": "DisclosureOfClassesOfShareCapitalAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "auth_ref": [ "r18" ], "lang": { "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } }, "en-us": { "role": { "label": "Schedule of Share Capital" } } }, "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "auth_ref": [ "r222" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "Disclosure of commitments and contingent liabilities [text block]", "verboseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES" } } }, "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilities" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDepositsFromBanksExplanatory": { "auth_ref": [ "r222" ], "lang": { "en": { "role": { "documentation": "The disclosure of deposits from banks. [Refer: Deposits from banks]" } }, "en-us": { "role": { "label": "SHORT-TERM BANK DEPOSITS" } } }, "localname": "DisclosureOfDepositsFromBanksExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/Short-termBankDeposits" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [abstract]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "auth_ref": [ "r245" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Schedule of Composition of Long-Term Bank Loan" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/Long-termLoansTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "auth_ref": [ "r245" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "auth_ref": [ "r133", "r138", "r143" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Schedule of Credit Risk" } } }, "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "auth_ref": [ "r64" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Schedule of Intangible Assets" } } }, "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Schedule of Composition of Property and Equipment and Related Accumulated Depreciation" } } }, "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r55" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "LOSS PER SHARE" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LossPerShare" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": { "auth_ref": [ "r99" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for fair value measurement." } }, "en-us": { "role": { "label": "Schedule of Fair Value Measurement of Warrants" } } }, "localname": "DisclosureOfFairValueMeasurementExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [abstract]" } } }, "localname": "DisclosureOfFinancialInstrumentsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r144" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for financial instruments." } }, "en-us": { "role": { "label": "FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT" } } }, "localname": "DisclosureOfFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagement" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]" } } }, "localname": "DisclosureOfFinancialInstrumentsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails", "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "auth_ref": [ "r133", "r138", "r143" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } } }, "localname": "DisclosureOfFinancialInstrumentsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails", "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of financial liabilities [line items]" } } }, "localname": "DisclosureOfFinancialLiabilitiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "auth_ref": [ "r143" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } }, "en-us": { "role": { "label": "Disclosure of financial liabilities [table]" } } }, "localname": "DisclosureOfFinancialLiabilitiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "auth_ref": [ "r5" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } }, "en-us": { "role": { "label": "GENERAL INFORMATION" } } }, "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/GeneralInformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "TAXES ON INCOME" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncome" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "auth_ref": [ "r123" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } }, "en-us": { "role": { "label": "Schedule of Assumptions Used to Value Options" } } }, "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [abstract]" } } }, "localname": "DisclosureOfIntangibleAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "auth_ref": [ "r67" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for intangible assets." } }, "en-us": { "role": { "label": "INTANGIBLE ASSETS" } } }, "localname": "DisclosureOfIntangibleAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]" } } }, "localname": "DisclosureOfIntangibleAssetsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails", "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "auth_ref": [ "r64" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } } }, "localname": "DisclosureOfIntangibleAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails", "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfLeasesExplanatory": { "auth_ref": [ "r110", "r111" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for leases." } }, "en-us": { "role": { "label": "LEASES" } } }, "localname": "DisclosureOfLeasesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": { "auth_ref": [ "r108" ], "lang": { "en": { "role": { "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } }, "en-us": { "role": { "label": "Schedule of Minimum Future Rental Payments" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of maturity analysis of operating lease payments [line items]" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": { "auth_ref": [ "r108" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments." } }, "en-us": { "role": { "label": "Disclosure of maturity analysis of operating lease payments [table]" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "auth_ref": [ "r26" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "auth_ref": [ "r119" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Schedule of Amounts Outstanding Under Employee Share Incentive Plan" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Schedule of Options Outstanding by Exercise Price Range" } } }, "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]" } } }, "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options." } }, "en-us": { "role": { "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]" } } }, "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [abstract]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r38" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } }, "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "auth_ref": [ "r105" ], "lang": { "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Schedule of Right-of-use assets" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [line items]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "auth_ref": [ "r105" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [table]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "auth_ref": [ "r188" ], "lang": { "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Schedule of Changes in Financial Liabilities With Cash Flows Included in Financing Activities" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "auth_ref": [ "r188" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } }, "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r48" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "TRANSACTIONS AND BALANCES WITH RELATED PARTIES" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedParties" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of risk management strategy related to hedge accounting [line items]" } } }, "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable": { "auth_ref": [ "r130" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the risk management strategy in relation to hedge accounting." } }, "en-us": { "role": { "label": "Disclosure of risk management strategy related to hedge accounting [table]" } } }, "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r19" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "EQUITY" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r165" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r121" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [abstract]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r45" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Schedule of Transactions With Related Parties" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r62" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Disposals, intangible assets other than goodwill", "negatedLabel": "Deletions during year" } } }, "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disposals, property, plant and equipment", "negatedLabel": "Deletions during year" } } }, "localname": "DisposalsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per share [abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r76", "r77" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EmployeeBenefitsExpense": { "auth_ref": [ "r0", "r25", "r166" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee benefit expense" } } }, "localname": "EmployeeBenefitsExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForBusinessCombinationsMember": { "auth_ref": [ "r126", "r128" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for business combinations [member]" } } }, "localname": "EntitysTotalForBusinessCombinationsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r47" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r9", "r15", "r81", "r83", "r95", "r96", "r97" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 10.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "BALANCE", "periodStartLabel": "BALANCE", "totalLabel": "Total equity" } } }, "localname": "Equity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r9" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and equity" } } }, "localname": "EquityAndLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and equity" } } }, "localname": "EquityAndLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityInterestsOfAcquirer": { "auth_ref": [ "r125" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Equity interests of acquirer", "terseLabel": "Equity consideration" } } }, "localname": "EquityInterestsOfAcquirer", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "localname": "EquityMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_EstimatedFinancialEffectOfContingentLiabilities": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "Contingent liability" } } }, "localname": "EstimatedFinancialEffectOfContingentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "auth_ref": [ "r122" ], "lang": { "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } }, "en-us": { "role": { "label": "Expected dividend yield (%)" } } }, "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfAssumptionsUsedToValueOptionsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_FeeAndCommissionExpense": { "auth_ref": [ "r230" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails": { "order": 0.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to fees and commissions." } }, "en-us": { "role": { "label": "Bank commissions" } } }, "localname": "FeeAndCommissionExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r22" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 30.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 }, "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance costs", "negatedLabel": "FINANCIAL EXPENSES", "totalLabel": "Financial expenses" } } }, "localname": "FinanceCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r230" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 20.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 }, "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "FINANCIAL INCOME", "totalLabel": "Financial income" } } }, "localname": "FinanceIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "auth_ref": [ "r132" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Fair value of the warrants" } } }, "localname": "FinancialLiabilitiesAtFairValue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": { "auth_ref": [ "r230" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } }, "en-us": { "role": { "label": "Change in fair value" } } }, "localname": "GainsLossesOnChangeInFairValueOfDerivatives", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r154", "r177", "r196", "r206" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical areas [axis]" } } }, "localname": "GeographicalAreasAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r154", "r177", "r196", "r206" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } }, "en-us": { "role": { "label": "Geographical areas [member]" } } }, "localname": "GeographicalAreasMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GrossCarryingAmountMember": { "auth_ref": [ "r32", "r60", "r69", "r72", "r127", "r137", "r139", "r201", "r248", "r249" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Cost [Member]", "verboseLabel": "Gross carrying amount [member]" } } }, "localname": "GrossCarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails", "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": { "auth_ref": [ "r198", "r199" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]" } }, "en-us": { "role": { "label": "Identifiable intangible assets recognised as of acquisition date", "verboseLabel": "Intangible assets acquired" } } }, "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r23", "r27", "r28", "r29", "r50", "r94", "r148" ], "calculation": { "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "totalLabel": "Taxes on income for the reported year" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "auth_ref": [ "r78" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents", "totalLabel": "INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities": { "auth_ref": [ "r97" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails": { "order": 10.0, "parentTag": "blrx_ProfitLossFromNonOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in the fair value measurement of liabilities. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Changes in fair value of warrants" } } }, "localname": "IncreaseDecreaseInFairValueMeasurementLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "auth_ref": [ "r223" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } }, "en-us": { "role": { "label": "Increase (decrease) through exercise of options, equity", "negatedLabel": "Employee stock options exercised", "terseLabel": "Employee stock options exercised" } } }, "localname": "IncreaseDecreaseThroughExerciseOfOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "auth_ref": [ "r223" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } }, "en-us": { "role": { "label": "Warrants exercised", "verboseLabel": "Warrants exercised" } } }, "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r3" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Share-based compensation", "verboseLabel": "Share-based compensation" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InsuranceExpense": { "auth_ref": [ "r225" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": { "order": 30.0, "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from purchased insurance." } }, "en-us": { "role": { "label": "Insurance" } } }, "localname": "InsuranceExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r7", "r63" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 20.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets, net", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "auth_ref": [ "r64", "r180", "r197" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill [member]" } } }, "localname": "IntangibleAssetsOtherThanGoodwillMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails", "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeAxis": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Intangible assets with indefinite useful life [Axis]", "verboseLabel": "Intangible assets with indefinite useful life [axis]" } } }, "localname": "IntangibleAssetsWithIndefiniteUsefulLifeAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLifeMember": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets with an indefinite useful life. It also represents the standard value for the 'Intangible assets with indefinite useful life' axis if no other member is used. [Refer: Intangible assets with indefinite useful life]" } } }, "localname": "IntangibleAssetsWithIndefiniteUsefulLifeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestExpense": { "auth_ref": [ "r93", "r146", "r153" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails": { "order": 10.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from interest." } }, "en-us": { "role": { "label": "Interest expense", "terseLabel": "Interest expense", "verboseLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestPayable": { "auth_ref": [ "r225" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": { "order": 30.0, "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of interest recognised as a liability." } }, "en-us": { "role": { "label": "Interest payable", "terseLabel": "Interest" } } }, "localname": "InterestPayable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentPropertyMember": { "auth_ref": [ "r192", "r194", "r225" ], "lang": { "en": { "role": { "documentation": "This member stands for investment property. It also represents the standard value for the 'Types of investment property' axis if no other member is used. [Refer: Investment property]" } }, "en-us": { "role": { "label": "Investment property [member]" } } }, "localname": "InvestmentPropertyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IssueOfEquity": { "auth_ref": [ "r3" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } }, "en-us": { "role": { "label": "Issuance of share capital, net", "verboseLabel": "Issuance of share capital and warrants, net" } } }, "localname": "IssueOfEquity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r171" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Ordinary shares" } } }, "localname": "IssuedCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Ordinary shares [Member]" } } }, "localname": "IssuedCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r44" ], "calculation": { "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Compensation cost", "totalLabel": "Benefits to key executive personnel" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits": { "auth_ref": [ "r42" ], "calculation": { "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails": { "order": 20.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Other long-term benefits" } } }, "localname": "KeyManagementPersonnelCompensationOtherLongtermBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "auth_ref": [ "r41" ], "calculation": { "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails": { "order": 30.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Post-employment benefits" } } }, "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r43" ], "calculation": { "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails": { "order": 10.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "verboseLabel": "Share-based compensation" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "auth_ref": [ "r40" ], "calculation": { "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails": { "order": 0.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Salaries and other short-term employee benefits" } } }, "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfKeyManagementCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LandAndBuildingsMember": { "auth_ref": [ "r174" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations. [Refer: Buildings; Land; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property [member]" } } }, "localname": "LandAndBuildingsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails", "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails", "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember": { "auth_ref": [ "r202", "r204", "r225" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than five years and not later than ten years." } }, "en-us": { "role": { "label": "2027-2030 [Member]" } } }, "localname": "LaterThanFiveYearsAndNotLaterThanTenYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "auth_ref": [ "r107", "r108", "r163", "r202", "r204", "r225" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } }, "en-us": { "role": { "label": "2024 [Member]" } } }, "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "auth_ref": [ "r107", "r108", "r163", "r202", "r204", "r225" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } }, "en-us": { "role": { "label": "2026 [Member]" } } }, "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "auth_ref": [ "r107", "r108", "r163", "r202", "r204", "r225" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } }, "en-us": { "role": { "label": "2025 [Member]" } } }, "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r102" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease liabilities [Default Label]", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year", "totalLabel": "Total lease liabilities" } } }, "localname": "LeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseholdImprovementsMember": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement." } }, "en-us": { "role": { "label": "Leasehold improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level3OfFairValueHierarchyMember": { "auth_ref": [ "r96" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } }, "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]", "verboseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "Level3OfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "auth_ref": [ "r39", "r96" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } } }, "localname": "LevelsOfFairValueHierarchyAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfFairValueMeasurementOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r9", "r95", "r96", "r97", "r149", "r152" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "terseLabel": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r188" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } }, "en-us": { "role": { "label": "Liabilities arising from financing activities", "periodEndLabel": "Balance as of December 31", "periodStartLabel": "Balance as of January 1" } } }, "localname": "LiabilitiesArisingFromFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "auth_ref": [ "r188" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Liabilities arising from financing activities [axis]" } } }, "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": { "auth_ref": [ "r188" ], "lang": { "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "localname": "LiabilitiesArisingFromFinancingActivitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LongtermBorrowingsMember": { "auth_ref": [ "r187", "r190" ], "lang": { "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Long-term loans [member]" } } }, "localname": "LongtermBorrowingsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LongtermDeposits": { "auth_ref": [ "r227" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 30.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } }, "en-us": { "role": { "label": "Long-term investment", "verboseLabel": "Initial seed capital to joint venture" } } }, "localname": "LongtermDeposits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r11", "r101", "r107", "r108", "r131", "r142", "r156", "r157", "r158", "r163", "r178", "r202" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails", "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MotorVehiclesMember": { "auth_ref": [ "r175" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing self-propelled ground vehicles used in the entity's operations. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Motor vehicles [member]" } } }, "localname": "MotorVehiclesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfLeaseLiabilitiesDetails", "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails", "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfUsefulLifeOfRightOfUseAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NetForeignExchangeGain": { "auth_ref": [ "r226", "r234" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails": { "order": 10.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange gain", "terseLabel": "Exchange differences, net" } } }, "localname": "NetForeignExchangeGain", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetForeignExchangeLoss": { "auth_ref": [ "r226", "r234" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails": { "order": 20.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange loss", "negatedLabel": "Foreign exchange loss", "terseLabel": "Exchange differences, net" } } }, "localname": "NetForeignExchangeLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r26" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsMember": { "auth_ref": [ "r26" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]" } } }, "localname": "NonadjustingEventsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r12", "r86", "r191" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 10.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CURRENT ASSETS" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r102" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 20.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Non-current lease liabilities", "verboseLabel": "Lease liabilities" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r13", "r88", "r191" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 10.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CURRENT LIABILITIES", "verboseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived": { "auth_ref": [ "r225" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The non-current portion of non-current loans received. [Refer: Loans received]" } }, "en-us": { "role": { "label": "Long-term loans, net of current maturities", "positiveLabel": "Long-term loans, net of current maturities", "terseLabel": "Long-term portion of loan", "verboseLabel": "Long-term bank loan, net of current maturities" } } }, "localname": "NoncurrentPortionOfNoncurrentLoansReceived", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentPrepayments": { "auth_ref": [ "r170" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current prepayments. [Refer: Prepayments]" } }, "en-us": { "role": { "label": "Long-term prepaid expenses" } } }, "localname": "NoncurrentPrepayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NotLaterThanOneYearMember": { "auth_ref": [ "r10", "r107", "r108", "r163", "r202", "r204" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } }, "en-us": { "role": { "label": "2023 [Member]" } } }, "localname": "NotLaterThanOneYearMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NumberOfEmployees": { "auth_ref": [ "r225" ], "lang": { "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } }, "en-us": { "role": { "label": "Number of individuals to which this benefit related" } } }, "localname": "NumberOfEmployees", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "auth_ref": [ "r244" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Option vested" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOutstandingShareOptions": { "auth_ref": [ "r113", "r117", "r120" ], "lang": { "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Option outstanding", "periodEndLabel": "Outstanding at end of year", "periodStartLabel": "Outstanding at beginning of year", "verboseLabel": "Number of options outstanding" } } }, "localname": "NumberOfOutstandingShareOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails", "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "auth_ref": [ "r118" ], "lang": { "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options exercisable in share-based payment arrangement", "periodEndLabel": "Exercisable at end of year" } } }, "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "auth_ref": [ "r116" ], "lang": { "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Options exercised", "negatedLabel": "Exercised" } } }, "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r115" ], "lang": { "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options forfeited in share-based payment arrangement", "negatedLabel": "Forfeited and expired" } } }, "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r114" ], "lang": { "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Granted" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesAuthorised": { "auth_ref": [ "r16" ], "lang": { "en": { "role": { "documentation": "The number of shares authorised." } }, "en-us": { "role": { "label": "Authorized share capital" } } }, "localname": "NumberOfSharesAuthorised", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r223" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Ordinary shares, issued", "verboseLabel": "Issuance of stock" } } }, "localname": "NumberOfSharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "auth_ref": [ "r17" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } }, "en-us": { "role": { "label": "Issued and paid-up share capital" } } }, "localname": "NumberOfSharesIssuedAndFullyPaid", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_OfficeEquipmentMember": { "auth_ref": [ "r176" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Office furniture and equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherComprehensiveIncome": { "auth_ref": [ "r2", "r21", "r24", "r89" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Other comprehensive income", "verboseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentPayables": { "auth_ref": [ "r227" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 20.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 }, "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other", "totalLabel": "Other" } } }, "localname": "OtherCurrentPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentReceivables": { "auth_ref": [ "r170" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 30.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 }, "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } }, "en-us": { "role": { "label": "Other receivables", "totalLabel": "Other receivables" } } }, "localname": "OtherCurrentReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherExpenseByFunction": { "auth_ref": [ "r25", "r49", "r167" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": { "order": 50.0, "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses." } }, "en-us": { "role": { "label": "Other expense, by function", "verboseLabel": "Other" } } }, "localname": "OtherExpenseByFunction", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherExpenseByNature": { "auth_ref": [ "r25", "r166" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 60.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Other expenses, by nature", "verboseLabel": "Other" } } }, "localname": "OtherExpenseByNature", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherFeeAndCommissionExpense": { "auth_ref": [ "r225" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fee and commission expense that the entity does not separately disclose in the same statement or note. [Refer: Fee and commission expense]" } }, "en-us": { "role": { "label": "Commitment fee" } } }, "localname": "OtherFeeAndCommissionExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherIntangibleAssetsMember": { "auth_ref": [ "r236" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intellectual property [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/INTANGIBLEASSETSNarrativeDetails", "http://biolinerx.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherPayables": { "auth_ref": [ "r227" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": { "order": 10.0, "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other payables", "verboseLabel": "Other" } } }, "localname": "OtherPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails", "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReceivables": { "auth_ref": [ "r170" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other receivables [Default Label]", "verboseLabel": "Other receivables" } } }, "localname": "OtherReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "auth_ref": [ "r28" ], "calculation": { "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": { "order": 30.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)", "verboseLabel": "Other" } } }, "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r186" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 50.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Repayments of lease liabilities" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PresentationOfLeasesForLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Presentation of leases for lessee [abstract]" } } }, "localname": "PresentationOfLeasesForLesseeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "terseLabel": "Net proceeds of loan", "verboseLabel": "Loan received" } } }, "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromExerciseOfOptions": { "auth_ref": [ "r240" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 20.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of options." } }, "en-us": { "role": { "label": "Proceeds from exercise of options", "terseLabel": "Employee stock options exercised" } } }, "localname": "ProceedsFromExerciseOfOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "auth_ref": [ "r240" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } }, "en-us": { "role": { "label": "Proceeds from exercise of warrants", "terseLabel": "Exercise of warrants" } } }, "localname": "ProceedsFromExerciseOfWarrants", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "auth_ref": [ "r240" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Net proceeds from transaction" } } }, "localname": "ProceedsFromIssueOfOrdinaryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": { "auth_ref": [ "r183" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 30.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Proceeds from issuing other equity instruments", "verboseLabel": "Proceeds from long-term loan, net of issuance costs" } } }, "localname": "ProceedsFromIssuingOtherEquityInstruments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r183" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Issuance of share capital and warrants, net of issuance cost", "terseLabel": "Issuance of share capital and warrants, net of issuance costs", "verboseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements", "http://biolinerx.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfessionalFeesExpense": { "auth_ref": [ "r225" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": { "order": 20.0, "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } }, "en-us": { "role": { "label": "Professional fees expense", "verboseLabel": "Professional fees" } } }, "localname": "ProfessionalFeesExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r1", "r20", "r74", "r82", "r84", "r149", "r150", "r191", "r205", "r207" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 }, "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Comprehensive loss for the year", "positiveTerseLabel": "Comprehensive loss for the year", "terseLabel": "Comprehensive loss for the year", "totalLabel": "LOSS AND COMPREHENSIVE LOSS", "verboseLabel": "Loss" } } }, "localname": "ProfitLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements", "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations [member]; Profit (loss) from continuing operations]" } }, "en-us": { "role": { "label": "Loss attributed to ordinary shares" } } }, "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r179", "r230" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "OPERATING LOSS" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r6", "r35" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 10.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property and equipment, net", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentMember": { "auth_ref": [ "r36", "r180", "r197" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/PropertyAndEquipmentScheduleOfCompositionOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationDetails", "http://biolinerx.com/role/SignificantAccountingPoliciesScheduleOfDepreciationRatesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "auth_ref": [ "r182" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 30.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Purchase of intangible assets, classified as investing activities", "negatedLabel": "Purchase of intangible assets" } } }, "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r182" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 20.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r100", "r120", "r158", "r193", "r195", "r245" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]", "verboseLabel": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails", "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails", "http://biolinerx.com/role/Long-termLoansNarrativeDetails", "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r100", "r120", "r158", "r193", "r195", "r245" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails", "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails", "http://biolinerx.com/role/Long-termLoansNarrativeDetails", "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [Axis]", "verboseLabel": "Ranges of exercise prices for outstanding share options [axis]" } } }, "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]" } } }, "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RepairsAndMaintenanceExpense": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses incurred for the day-to-day servicing of assets, which may include the cost of labour, consumables or small parts." } }, "en-us": { "role": { "label": "Building maintenance charges" } } }, "localname": "RepairsAndMaintenanceExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [ "r185" ], "calculation": { "http://biolinerx.com/role/ConsolidatedCashFlowStatements": { "order": 40.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Repayments of borrowings, classified as financing activities", "negatedLabel": "Repayments of loans", "negatedTerseLabel": "Principal and interest payments", "verboseLabel": "Repayment of loan and Interest" } } }, "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedCashFlowStatements", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfChangesInFinancialLiabilitiesWithCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r66" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 }, "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES", "totalLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreads": { "auth_ref": [ "r155", "r228" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the accumulated change in the value of foreign currency basis spreads of financial instruments when excluding them from the designation of these financial instruments as hedging instruments." } }, "en-us": { "role": { "label": "Value on balance sheet" } } }, "localname": "ReserveOfChangeInValueOfForeignCurrencyBasisSpreads", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfSensitivityAnalysisDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r171", "r172" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 50.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarnings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/GeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r4", "r168" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Accumulated deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RevenueFromInterest": { "auth_ref": [ "r92", "r145", "r153", "r225" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails": { "order": 0.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income arising from interest." } }, "en-us": { "role": { "label": "Interest income", "terseLabel": "Interest income" } } }, "localname": "RevenueFromInterest", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfFinancialIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r104" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 40.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Right-of-use assets, net", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year" } } }, "localname": "RightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biolinerx.com/role/LeasesScheduleOfRight-of-useAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SalesAndMarketingExpense": { "auth_ref": [ "r230" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 10.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 }, "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } }, "en-us": { "role": { "label": "Sales and marketing expense", "negatedLabel": "SALES AND MARKETING EXPENSES", "totalLabel": "Sales and marketing expenses" } } }, "localname": "SalesAndMarketingExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r230" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 20.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 }, "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to selling, general and administrative activities of the entity." } }, "en-us": { "role": { "label": "Selling, general and administrative expense", "negatedLabel": "GENERAL AND ADMINISTRATIVE EXPENSES", "totalLabel": "General and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": { "auth_ref": [ "r141" ], "lang": { "en": { "role": { "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]" } }, "en-us": { "role": { "label": "Schedule of Sensitivity Analysis" } } }, "localname": "SensitivityAnalysisForEachTypeOfMarketRisk", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_SeparateManagementEntitiesAxis": { "auth_ref": [ "r46" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Separate management entities [Axis]", "verboseLabel": "Separate management entities [axis]" } } }, "localname": "SeparateManagementEntitiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_SeparateManagementEntitiesMember": { "auth_ref": [ "r46" ], "lang": { "en": { "role": { "documentation": "This member stands for separate entities that provide key management personnel services to the entity. It also represents the standard value for the 'Separate management entities' axis if no other member is used. [Refer: Key management personnel of entity or parent [member]]" } } }, "localname": "SeparateManagementEntitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TransactionsAndBalancesWithRelatedPartiesScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ServicesExpense": { "auth_ref": [ "r230" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 0.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from services." } }, "en-us": { "role": { "label": "Research and development services" } } }, "localname": "ServicesExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShareIssueRelatedCost": { "auth_ref": [ "r223" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails": { "order": 0.0, "parentTag": "blrx_ProfitLossFromNonOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } }, "en-us": { "role": { "label": "Issuance expense", "negatedLabel": "Issuance costs" } } }, "localname": "ShareIssueRelatedCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfNon-operatingIncomeExpensesNetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremium": { "auth_ref": [ "r171" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 10.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium" } } }, "localname": "SharePremium", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium [Member]" } } }, "localname": "SharePremiumMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_SharebasedPaymentArrangementsMember": { "auth_ref": [ "r121" ], "lang": { "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "localname": "SharebasedPaymentArrangementsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "auth_ref": [ "r243" ], "calculation": { "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails": { "order": 10.0, "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "verboseLabel": "Short-term bank deposits" } } }, "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "auth_ref": [ "r227" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Short term bank deposits", "verboseLabel": "Short-term bank deposits" } } }, "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShorttermEmployeeBenefitsExpense": { "auth_ref": [ "r225" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails": { "order": 10.0, "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services." } }, "en-us": { "role": { "label": "Short-term employee benefits expense", "verboseLabel": "Payroll and related expenses" } } }, "localname": "ShorttermEmployeeBenefitsExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents": { "auth_ref": [ "r243" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 10.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Short-term bank deposits" } } }, "localname": "ShorttermInvestmentsClassifiedAsCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "auth_ref": [ "r28" ], "calculation": { "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails": { "order": 0.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Theoretical tax benefit" } } }, "localname": "TaxExpenseIncomeAtApplicableTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/TaxesOnIncomeScheduleOfReconciliationOfWeightedAverageTaxRateApplicableToIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r100", "r120", "r158", "r193", "r195", "r245" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range [member]", "verboseLabel": "Top of range [member]" } } }, "localname": "TopOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/CashAndCashEquivalentsNarrativeDetails", "http://biolinerx.com/role/CommitmentsAndContingentLiabilitiesDetails", "http://biolinerx.com/role/Long-termLoansNarrativeDetails", "http://biolinerx.com/role/Short-termBankDepositsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts payable and accruals:" } } }, "localname": "TradeAndOtherCurrentPayablesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "auth_ref": [ "r169", "r229" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 10.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } }, "en-us": { "role": { "label": "Trade" } } }, "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accruals:" } } }, "localname": "TradeAndOtherPayablesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": { "auth_ref": [ "r229" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business." } }, "en-us": { "role": { "label": "Trade payables [Default Label]", "totalLabel": "Trade", "verboseLabel": "Trade" } } }, "localname": "TradeAndOtherPayablesToTradeSuppliers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails", "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfAccountsPayableAndAccrualsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TravelExpense": { "auth_ref": [ "r225" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails": { "order": 20.0, "parentTag": "ifrs-full_SalesAndMarketingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from travel." } }, "en-us": { "role": { "label": "Overseas travel" } } }, "localname": "TravelExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfSalesAndMarketingExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TypesOfInvestmentPropertyAxis": { "auth_ref": [ "r225" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of investment property [axis]", "verboseLabel": "Types of investment property [axis]" } } }, "localname": "TypesOfInvestmentPropertyAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/Long-termLoansNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksAxis": { "auth_ref": [ "r129", "r134", "r135", "r159", "r160", "r161", "r162" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of risks [Axis]", "verboseLabel": "Types of risks [axis]" } } }, "localname": "TypesOfRisksAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksMember": { "auth_ref": [ "r129", "r134", "r135", "r159", "r160", "r161", "r162" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } }, "en-us": { "role": { "label": "Risks [member]" } } }, "localname": "TypesOfRisksMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfConcentrationOfCurrencyRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfCreditRiskDetails", "http://biolinerx.com/role/FinancialInstrumentsAndFinancialRiskManagementScheduleOfLinkageOfMonetaryItemsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r121" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of share-based payment arrangements [Axis]", "verboseLabel": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r108" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of undiscounted operating lease payments to be received. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } }, "en-us": { "role": { "label": "Minimum future rental payments" } } }, "localname": "UndiscountedOperatingLeasePaymentsToBeReceived", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/LeasesScheduleOfMinimumFutureRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WagesAndSalaries": { "auth_ref": [ "r233" ], "calculation": { "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails": { "order": 0.0, "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Wages and salaries", "verboseLabel": "Payroll and related expenses" } } }, "localname": "WagesAndSalaries", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SupplementaryFinancialStatementInformationScheduleOfGeneralAndAdministrativeExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WarrantReserve": { "auth_ref": [ "r228" ], "calculation": { "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 20.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]" } }, "en-us": { "role": { "label": "Warrant reserve", "terseLabel": "Warrants" } } }, "localname": "WarrantReserve", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WarrantReserveMember": { "auth_ref": [ "r224" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments [member]]" } }, "en-us": { "role": { "label": "Warrant reserve [member]", "verboseLabel": "Warrants [Member]" } } }, "localname": "WarrantReserveMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "auth_ref": [ "r118" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement", "periodEndLabel": "Exercisable at end of year" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r116" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Exercised", "verboseLabel": "Weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r115" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Forfeited and expired" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r114" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price", "verboseLabel": "Granted" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "auth_ref": [ "r113", "r117" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding at end of year", "periodStartLabel": "Outstanding at beginning of year", "terseLabel": "Weighted average exercise price outstanding" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/EquityScheduleOfAmountsOutstandingUnderEmployeeShareIncentivePlanDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": { "auth_ref": [ "r109" ], "lang": { "en": { "role": { "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment." } }, "en-us": { "role": { "label": "Weighted average incremental borrowing rate on lease liabilities" } } }, "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average contractual life", "verboseLabel": "Weighted average remaining contractual (in yrs.)" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/EquityNarrativeDetails", "http://biolinerx.com/role/EquityScheduleOfOptionsOutstandingByExercisePriceRangeDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r54" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Number of shares used in basic calculation", "verboseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE" } } }, "localname": "WeightedAverageShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://biolinerx.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://biolinerx.com/role/LossPerShareScheduleOfBasicLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://biolinerx.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r10": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r100": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "59", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_59&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "C12", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r110": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Clause": "vi", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r120": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r130": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "22A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_22A&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r140": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r150": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "9", "Paragraph": "6.5.16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_6.5.16&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r160": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r167": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r168": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r169": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r17": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r170": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r171": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r172": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r173": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "22", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r174": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r175": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r176": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r177": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r178": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r179": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r18": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r180": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r181": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r182": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r183": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r184": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r185": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r186": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r187": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r188": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r189": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r19": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r190": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r191": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r192": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r193": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r194": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "IE60", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r195": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r196": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r197": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r198": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r199": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "IE72", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_IE72&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r2": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r20": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r200": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r201": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r202": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r203": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r204": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r205": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r206": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r207": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r208": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "36", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_c&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r209": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r21": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r210": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG24_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r211": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG25", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG25_b&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r212": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r213": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r214": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r215": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r216": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r217": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r218": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r219": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r22": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r220": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r221": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r222": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r223": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r224": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r225": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r226": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r227": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r228": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r229": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r23": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r230": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r231": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r232": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r233": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_9&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r234": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r235": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r236": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r237": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r238": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r239": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r24": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r240": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r241": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r242": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r243": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r244": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r245": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r246": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Effective 2023-01-01", "Number": "1", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r247": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r248": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r249": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r25": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r30": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS16_g73-79__IAS16_g73-79_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r40": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "18A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18A&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_vii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_51&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r50": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Paragraph": "86", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_86_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r60": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS38_g118-128__IAS38_g118-128_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r70": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_46&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r80": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r90": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS13_g91-99__IFRS13_g91-99_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" }